Peptidic linker with reduced post-translational modification
By employing glycine-serine peptide linkers without C-terminal serine residues, post-translational modifications are minimized, leading to more homogeneous fusion polypeptide production in eukaryotic cells, addressing the heterogeneity issue in recombinant production.
Patent Information
- Application Number
- JP2024135512
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-06-08
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing peptide linkers in recombinant production of fusion polypeptides in eukaryotic cells lead to increased heterogeneity due to post-translational modifications, particularly affecting serine residues, which complicates the production of homogeneous fusion polypeptide preparations.
The use of glycine-serine peptide linkers devoid of a C-terminal serine residue, or all serine residues, to reduce or eliminate post-translational modifications such as phosphorylation and glycosylation, by ensuring the absence of serine, threonine, and proline at the C-terminus of the linker.
This approach results in more homogeneous recombinantly produced fusion polypeptides with reduced post-translational modifications, enhancing the consistency and quality of the final product.
Smart Images

Figure 2024164077000031 
Figure 2024164077000032 
Figure 2024164077000033
Abstract
Description
[Technical field]
[0001] The present invention is in the field of recombinant polypeptide production. More specifically, new peptide linkers are reported herein that result in less post-translational modifications and therefore less product heterogeneity, especially in the recombinant production of fusion polypeptides. [Background technology]
[0002] 2. Background of the Invention The introduction of recombinantly produced multispecific antibodies in eukaryotic cells has led to the development of a number of different molecular formats. Some of these use domain architectures in which different, non-naturally associated domains are fused to each other using a linker. If recombinant production of the fusion polypeptide is intended, this linker needs to be a codable linker, such as a peptide linker.
[0003] Peptide linkers are synthetic amino acid sequences employed to connect different polypeptide domains. They generally consist of a linear chain of amino acids, the 20 naturally occurring amino acids being monomeric building blocks connected by peptide bonds. The peptide linkers can have a length of 1 to 50 amino acid residues, with a length of 3 to 25 amino acid residues being chosen in most cases. The peptide linkers can contain repetitive amino acid sequences. The peptide linkers have the function of ensuring that the modules connected by the linker are able to carry out their biological activity by allowing the domains to fold correctly and be properly presented. Most often, the peptide linkers are synthetic peptide linkers that are specified to be rich in glycine, glutamine, and / or serine residues. These residues are arranged in small repeating units of up to 5 amino acids, such as GGGS or GGGGS (SEQ ID NOs: 16 and 17, respectively). The small repeating units are repeated 2 to 5 times, e.g., (GGGS) 2 or (GGGGS)2 It is possible to form polymeric units such as:
[0004] Unfortunately, during the recombinant production of fusion polypeptides that contain peptide linkers in eukaryotic host cells, the amino acid residues in the peptide linker may serve as substrates for in vivo post-translational modification.Addition of post-translational modification increases the heterogeneity of recombinantly produced fusion polypeptides.Therefore, new peptide linkers that reduce or even eliminate the addition of post-translational modification will allow the recombinant production of more homogeneous fusion polypeptide preparations.
[0005] In the publication by Spahr et al. (MAbs 9 (2017) 812-819 (Non-Patent Document 1)), a hydroxyproline in the GGGGP (SEQ ID NO: 18) linker was reported.
[0006] Shi, Y. reported biochemical and structural studies that advance the understanding of the mechanisms of the three major classes of protein serine / threonine phosphatases, focusing on PP2A (Cell 139 (2009) 468-484 (Non-Patent Document 2)).
[0007] Basle, E. et al. reported on the chemical modification of endogenous amino acids in proteins (Chem. Biol. 17 (2010) 213-227 (Non-Patent Document 3)).
[0008] WO2003 / 062276 (Patent Document 1) disclosed polypeptide mutants comprising ligand-binding domains of cytokines linked via flexible polypeptide linker molecules.
[0009] WO2011 / 161260 (Patent Document 2) disclosed an anti-cancer fusion protein.
[0010] WO2012 / 088461 (Patent Document 3) disclosed that a linker peptide lacking the amino acid sequence GSG reduces or eliminates the addition of post-translational modifications to a polypeptide comprising the linker peptide.
[0011] WO2014 / 085621 (Patent Document 4) disclosed therapeutic fusion proteins useful for treating lysosomal diseases and methods for treating such diseases.
[0012] WO2015 / 091130 (Patent Document 5) disclosed a method for recombinantly producing a polypeptide in a soluble form, comprising the steps of transfecting a eukaryotic cell with a nucleic acid encoding a polypeptide, whereby the polypeptide is modified (compared to a wild-type polypeptide) by the introduction of one or more artificial glycosylation sites, culturing the transfected cells in a culture medium, and recovering the polypeptide from the culture medium, whereby the yield of monomeric polypeptide (determined after one purification step) is increased by at least 100% compared to the wild-type polypeptide.
[0013] WO2016 / 115511 (Patent Document 6) disclosed a VEGF variant polypeptide composition.
[0014] WO2011 / 161260 (Patent Document 2) disclosed a fusion protein comprising domain (a), which is a functional fragment of a soluble hTRAIL protein sequence, and domain (b), which is the sequence of a pro-apoptotic effector peptide.
[0015] WO2016 / 120216 (Patent Document 7) discloses a polypeptide encoding a chimeric antigen receptor comprising at least one extracellular binding domain comprising an scFv formed by at least a VH chain and a VL chain specific for an antigen, the extracellular binding domain comprising at least one mAb-specific epitope.
[0016] Spencer, D. et al. disclosed that O-xylosylation in recombinant proteins is directed to a consensus motif of glycine-serine linkers (J. Pharm. Sci 102 (2013) 3920-3924 (Non-Patent Document 4)).
[0017] Wen, D. et al. disclosed an investigation of O-xylosylation in engineered proteins containing (GGGGS)n (SEQ ID NO: 17) linkers (Anal. Chem. 85 (2013) 4805-4812 (Non-Patent Document 5)).
[0018] Peter-Katalinic, J. disclosed that cell surface and extracellular proteins are O-glycosylated, where the most abundant type of O-glycosylation in proteins is GalNAc linked to serine or threonine in the protein chain by a glycosidic bond (Meth. Enzymol. 405 (2005) 139-171 (Non-Patent Document 6)).
[0019] Plomp, R. et al. disclosed O-glycosylation of the hinge region of human immunoglobulin G3 (Mol. Cell. Prot. 14 (2015) 1373-1384 (Non-Patent Document 7)).
[0020] U.S. Patent No. 9,409,960 (Patent Document 8) discloses linker peptides and polypeptides containing the linker peptides, where the linker peptide lacks the amino acid sequence GSG, reducing or eliminating the addition of post-translational modifications to the polypeptides containing the linker peptides. [Prior art documents] [Patent documents]
[0021] [Patent Document 1] WO2003 / 062276 [Patent Document 2] WO2011 / 161260 [Patent Document 3] WO2012 / 088461
Patent Document 4
Patent Document 5
Patent Document 6
Patent Document 7
Patent Document 8
Non-Patent Document
[0022]
Non-Patent Document 1
Non-Patent Document 2
Non-Patent Document 3
Non-Patent Document 4
Non-Patent Document 5
Non-Patent Document 6
Non-Patent Document 7
Summary of the Invention
[0023] Summary The present invention is based, at least in part, on the discovery that a glycine-serine peptide linker lacking at least a C-terminal serine residue, or even all serine residues resulting in a pure glycine linker, reduces or even eliminates the addition of post-translational modifications to a fusion polypeptide that contains such a post-translational modification. To achieve this, the polypeptide at the C-terminus of the peptide linker shall not contain a serine, threonine or proline residue present at its N-terminus, i.e., the first amino acid residue after the peptide linker shall not be a serine, threonine or proline residue.
[0024] More specifically, the peptide linkers reported herein reduce or even eliminate the ability of enzymes to add post-translational modifications, such as phosphate groups or carbohydrate moieties, to fusion polypeptides containing such peptide linkers, e.g., reducing the ability of xylosyltransferase to link xylose to serine residues.
[0025] Thus, the inclusion of a peptide linker as reported herein in a fusion polypeptide can increase the homogeneity of recombinantly (in eukaryotic cells) produced fusion polypeptide compositions and preparations.
[0026] One aspect of the present invention is the amino acid sequence GyX1 (SEQ ID NO: 4) wherein X1 can be any amino acid residue except serine, threonine, and proline; and A fusion polypeptide comprising an amino acid sequence in which y is an integer of 3 to 25, inclusive.
[0027] In one embodiment, the fusion polypeptide comprises the amino acid sequence GyX1X2X3 (SEQ ID NO:5) wherein X1 can be any amino acid residue except serine, threonine, and proline; X2 and X3 can be, independently of each other, any amino acid residue; and A fusion polypeptide comprising an amino acid sequence in which y is an integer of 3 to 25, inclusive.
[0028] In one embodiment, y is an integer between 4 and 20, inclusive.
[0029] In one embodiment, y is an integer between 5 and 15, inclusive.
[0030] One aspect of the present invention is the amino acid sequence GnSGmX1 (SEQ ID NO: 1) wherein X1 can be any amino acid residue except serine, threonine, and proline; n=1, 2, 3 or 4, and A fusion polypeptide comprising an amino acid sequence, wherein m=3, 4 or 5.
[0031] In one embodiment of all aspects of the invention, the fusion polypeptide has the amino acid sequence GnSGmX1X2X3 (SEQ ID NO: 2) wherein X1 can be any amino acid residue except serine, threonine, and proline; X2 and X3 can be, independently of each other, any amino acid residue; n=1, 2, 3 or 4, and A fusion polypeptide comprising an amino acid sequence, wherein m=3, 4 or 5.
[0032] In one embodiment of all aspects of the invention, the fusion polypeptide comprises at least three domains: wherein each of the three domains, independently of the other two domains, is a polypeptide at least 10 amino acid residues in length; and The domains are coupled to each other via peptide bonds.
[0033] In one embodiment of all aspects of the invention, the C-terminus of the first domain is conjugated to the N-terminus of the second domain via a peptide bond, and the C-terminus of the second domain is conjugated to the N-terminus of the third domain via a peptide bond.
[0034] In one embodiment of all aspects of the invention, the fusion polypeptide is a recombinant fusion polypeptide.
[0035] In one embodiment of all aspects of the invention, the fusion polypeptide is produced in a eukaryotic cell.
[0036] In one embodiment of all aspects of the invention, the fusion polypeptide has no post-translational modifications at S or X1 of SEQ ID NO:1.
[0037] In one embodiment of all aspects of the invention, the linear fusion polypeptide has no post-translational modification at X1 of SEQ ID NO:1.
[0038] In one embodiment of all aspects of the invention, the post-translational modification is phosphorylation (addition of a phosphate group) and / or glycosylation (addition of a carbohydrate moiety). In one embodiment of all aspects of the invention, the glycosylation is xylosylation (the carbohydrate moiety is xylose). In one embodiment of all aspects of the invention, the glycosylation is glucosylation (the carbohydrate moiety is glucose).
[0039] In one embodiment of all aspects of the invention, the fusion polypeptide comprises: GnSGmX1X2X3 (SEQ ID NO: 6) A fusion polypeptide comprising: X1 is serine, threonine, or proline; X2 and X3 can be, independently of each other, any amino acid residue; n=1, 2, 3 or 4, and Fusion polypeptides, where m=3, 4 or 5. has reduced post-translational modifications at residues S and / or X1 compared to
[0040] In one embodiment of all aspects of the invention, n is 3 and m is 3 or 4. In a preferred embodiment of all aspects of the invention, n is 3 and m is 4.
[0041] In one embodiment of all aspects of the invention, n is 4 and m is 4 or 5. In a preferred embodiment of all aspects of the invention, n is 4 and m is 5.
[0042] In one embodiment of all aspects of the invention, the fusion polypeptide has the amino acid sequence GpSGnSGmX1X2X3 (SEQ ID NO: 3) wherein X1 can be any amino acid residue except serine, threonine, and proline; X2 and X3 can be, independently of each other, any amino acid residue; n is 3 or 4; m=3, 4, or 5, and The amino acid sequence includes an amino acid sequence in which p=3 or 4.
[0043] In one embodiment of all aspects of the invention, the fusion polypeptide further comprises an antibody Fc region polypeptide / at least one domain is an antibody Fc region polypeptide.
[0044] In one embodiment of all aspects of the invention, the first or / and third domain is an antibody Fc region polypeptide.
[0045] In one embodiment of all aspects of the invention, the fusion polypeptide further comprises a VH domain, a VL domain, an scFv, an scFab, a VH-CH1 pair, a VL-CL pair, a VH-CL pair, a VL-CH1 pair, a receptor or an extracellular domain thereof, a receptor-binding portion of a ligand, an enzyme, a growth factor, an interleukin, a cytokine, or a chemokine.
[0046] In one embodiment of all aspects of the invention, the fusion polypeptide further comprises at least one domain selected from the group consisting of a VH domain, a VL domain, an scFv, an scFab, a VH-CH1 pair, a VL-CL pair, a VH-CL pair, a VL-CH1 pair, a receptor or an extracellular domain thereof, a receptor-binding portion of a ligand, an enzyme, a growth factor, an interleukin, a cytokine, and a chemokine.
[0047] In one embodiment of all aspects of the invention, the fusion polypeptide is monomeric.
[0048] In one embodiment of all aspects of the invention, the fusion polypeptide is a linear fusion polypeptide.
[0049] Another aspect of the present invention is a multimeric molecule comprising at least two polypeptides, at least one of which is a fusion polypeptide as reported herein.
[0050] In one embodiment of all aspects of the invention, the at least two polypeptides are coupled to each other by one or more disulfide bonds.
[0051] In one embodiment of all aspects of the invention, the multimeric molecule is an antibody.
[0052] In one embodiment of all aspects of the invention, the multimeric molecule is a bispecific antibody.
[0053] In one embodiment of all aspects of the invention, the multimeric molecule further comprises at least one antibody light chain.
[0054] In one embodiment of all aspects of the invention, the multimeric molecule further comprises at least one antibody heavy chain.
[0055] Another aspect of the present invention is a pharmaceutical formulation comprising at least one fusion polypeptide as reported herein or a multimeric molecule as reported herein, and optionally a pharma- ceutically acceptable carrier.
[0056] A further aspect of the invention is a nucleic acid molecule encoding the fusion polypeptide as reported herein.
[0057] In one embodiment of all aspects of the invention, the nucleic acid molecule is in an expression cassette.
[0058] In one embodiment of all aspects of the invention, the nucleic acid molecule is in a vector.
[0059] Also an aspect of the invention is a set of nucleic acid molecules that encode the polypeptides of the multimeric molecules reported herein.
[0060] In one embodiment of all aspects of the invention, each of the nucleic acid molecules is in an expression cassette.
[0061] In one embodiment of all aspects of the invention, each of the nucleic acid molecules is in a vector.
[0062] In one embodiment of all aspects of the invention, the nucleic acid molecules are on the same vector.
[0063] In one embodiment of all aspects of the invention, the nucleic acid molecules are on different vectors.
[0064] In one embodiment of all aspects of the invention, the nucleic acid molecule is on two vectors.
[0065] A further aspect as reported herein is a eukaryotic cell comprising a nucleic acid molecule as reported herein or a set of nucleic acid molecules as reported herein.
[0066] Another aspect of the invention is the amino acid sequence GyX1 (SEQ ID NO: 4) wherein X1 can be any amino acid residue except serine, threonine, and proline; A peptide linker comprising an amino acid sequence, wherein y is an integer of 3 to 25, inclusive.
[0067] Another aspect of the invention is the amino acid sequence GyX1X2X3 (SEQ ID NO:5) wherein X1 can be any amino acid residue except serine, threonine, and proline; X2 and X3 can be, independently of each other, any amino acid residue; and A peptide linker comprising an amino acid sequence, wherein y is an integer of 3 to 25, inclusive.
[0068] In one embodiment, y is an integer between 4 and 20, inclusive.
[0069] In one embodiment, y is an integer between 5 and 15, inclusive.
[0070] Another aspect of the invention is the amino acid sequence GnSGmX1 (SEQ ID NO: 1) wherein X1 can be any amino acid residue except serine, threonine, and proline; n=1, 2, 3 or 4, and m=3, 4 or 5.
[0071] Another aspect of the invention is the amino acid sequence GnSGmX1X2X3 (SEQ ID NO: 2) wherein X1 can be any amino acid residue except serine, threonine, and proline; X2 and X3 can be, independently of each other, any amino acid residue; n=1, 2, 3 or 4, and m=3, 4 or 5.
[0072] Another aspect of the invention is the amino acid sequence GpSGnSGmX1X2X3 (SEQ ID NO: 3) wherein X1 can be any amino acid residue except serine, threonine, and proline; X2 and X3 can be, independently of each other, any amino acid residue; n=1, 2, 3 or 4; m=3, 4, or 5, and p=3 or 4.
[0073] Another aspect of the invention is a method for producing a fusion polypeptide comprising the steps of: - culturing a eukaryotic cell according to the invention under conditions in which the fusion polypeptide is expressed, and - Recovering the fusion polypeptide from the eukaryotic cell or the culture medium. Thereby producing a fusion polypeptide.
[0074] Another aspect of the invention is a method for producing a fusion polypeptide having a reduced level of post-translational modification comprising: - culturing the host cell of claim 38 under conditions in which the fusion polypeptide is expressed; and recovering the fusion polypeptide from the eukaryotic cell or culture medium; Thereby producing a fusion polypeptide having a reduced level of post-translational modification.
[0075] A further aspect of the invention is a method of producing a stabilized fusion polypeptide comprising genetically engineering a fusion protein to include a peptide linker of the invention and expressing the fusion polypeptide by a eukaryotic cell, thereby producing a stabilized fusion polypeptide.
[0076] Also an aspect of the invention is a composition made by the method according to the invention.
[0077] A further aspect of the present invention is a method for treating a subject who would benefit from treatment with a fusion polypeptide according to the present invention or a multimeric molecule according to the present invention, comprising administering to the subject a composition according to the present invention.
[0078] A further aspect of the present invention is the use of a composition according to the present invention for the treatment of a disease or disorder.
[0079] Also an aspect of the invention is the use of a composition according to the invention for the manufacture of a medicament.
[0080] A further aspect of the present invention is a fusion polypeptide according to the invention, or a multimeric molecule according to the invention, for use as a medicament.
[0081] An aspect of the present invention is also the use of a fusion polypeptide according to the invention or a multimeric molecule according to the invention in the manufacture of a medicament.
[0082] A final aspect of the invention is a method for treating an individual in need of treatment, comprising administering to said individual an effective amount of a fusion polypeptide according to the invention or a multimeric molecule according to the invention. [The present invention 1001] A linear fusion polypeptide comprising a first polypeptide domain, a peptide linker, and a second polypeptide domain, the C-terminus of the first polypeptide domain is conjugated to the N-terminus of the peptide linker via a peptide bond, and the C-terminus of the peptide linker is conjugated to the N-terminus of the second polypeptide domain via a peptide bond; the peptide linker is a Gly / Ser peptide linker lacking a C-terminal serine amino acid residue, the second polypeptide domain comprises at its N-terminus any amino acid residue except serine, threonine, or proline; A linear fusion polypeptide, wherein the first or the second polypeptide domain is an antibody Fc region polypeptide and each other polypeptide is selected from the group consisting of a VH domain, a VL domain, an scFv, an scFab, a VH-CH1 pair, a VL-CL pair, a VH-CL pair, a VL-CH1 pair, a receptor or an extracellular domain thereof, a receptor binding portion of a ligand, an enzyme, a growth factor, an interleukin, a cytokine, or a chemokine. [The present invention 1002] The linear fusion polypeptide has the amino acid sequence GnSGmX1 (SEQ ID NO: 2) wherein GnSGm is a peptide linker with n=3 or 4 and m=3 or 4; 1001. The linear fusion polypeptide of the present invention, wherein X1 is the N-terminal amino acid residue of said second polypeptide. [The present invention 1003] The linear fusion polypeptide of claim 1001 or 1002, wherein said linear fusion polypeptide has reduced O-glycosylation compared to a fusion polypeptide in which said second polypeptide has a serine or threonine or proline at its N-terminus. [The present invention 1004] At least two polypeptides, at least one of which is a linear fusion polypeptide according to any one of claims 1001 to 1003. A polymeric molecule comprising: [The present invention 1005] The multimeric molecule of the present invention, wherein the multimeric molecule is an antibody. [The present invention 1006] A nucleic acid molecule encoding any one of the fusion polypeptides of the present inventions 1001 to 1003. [The present invention 1007] A eukaryotic cell comprising a nucleic acid molecule of the present invention 1006. [The present invention 1008] 1. A method for producing a linear fusion polypeptide having reduced levels of O-glycosylation, comprising: - culturing a host cell of the invention 1007 under conditions in which said fusion polypeptide is expressed; and - recovering said fusion polypeptide from said eukaryotic cell or from said culture medium; Thereby, producing a fusion polypeptide having a reduced level of O-glycosylation. A method comprising: DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0083] Detailed Description of the Invention Embodiments The present invention is based, at least in part, on the discovery that the use of a glycine-serine peptide linker that lacks a C-terminal serine residue reduces or even eliminates the addition of post-translational modifications to the peptide linker, particularly when the peptide linker is included in a fusion polypeptide. To achieve this, the polypeptide C-terminal to the peptide linker also does not contain a serine, threonine, or proline residue present at its N-terminus.
[0084] More specifically, the peptide linkers reported herein reduce the ability of enzymes to link secondary modifications, such as phosphate groups or carbohydrate moieties, to fusion polypeptides containing such peptide linkers, e.g., reduce the ability of xylosyltransferase to link xylose to a polypeptide.
[0085] Thus, the use of peptide linkers as reported herein in fusion polypeptides can increase the homogeneity of recombinantly (in eukaryotic cells) produced fusion polypeptide compositions and preparations.
[0086] General information regarding the nucleotide sequences of human immunoglobulin light and heavy chains is given in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991). The amino acid positions of all constant regions and domains of the heavy and light chains can be numbered according to the Kabat numbering system described in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991), and is referred to herein as the "Kabat numbering." Specifically, the Kabat numbering system of Kabat, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) (see pages 647-660) is used for the light chain constant domains CL of kappa and lambda isotypes, and the Kabat EU index numbering system (see pages 661-723) is used for the heavy chain constant domains (CH1, hinge, CH2 and CH3, which is further clarified herein by referring to the "Kabat EU index numbering" in this case).
[0087] As used herein and in the appended claims, the singular forms "a," "an," and "the" include the plural unless the context clearly dictates otherwise. Thus, for example, a reference to a "cell" includes a plurality of such cells and equivalents thereof known in the art, and so forth. Similarly, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein.
[0088] It should also be noted that the terms "comprising," "including," and "having" can be used interchangeably.
[0089] The skilled artisan is well aware of procedures and methods for converting, for example, the amino acid sequence of a peptide linker or fusion polypeptide into the corresponding coding nucleic acid sequence. Thus, a nucleic acid is characterized by its nucleic acid sequence consisting of individual nucleotides, as well as the amino acid sequence of the peptide linker or fusion polypeptide encoded by said nucleic acid sequence.
[0090] The use of recombinant DNA technology allows the production of derivatives of nucleic acids. Such derivatives can be modified, for example, by substitution, alteration, replacement, deletion or insertion, at individual or several nucleotide positions. The modification or derivatization can be carried out, for example, by site-directed mutagenesis. Such modifications can be easily carried out by those skilled in the art (e.g., Sambrook, J., et al., Molecular Cloning: A laboratory manual (1999) Cold Spring Harbor Laboratory Press, New York, USA; Hames, BD, and Higgins, SG, Nucleic acid hybridization-a practical approach (1985) IRL Press, Oxford, England).
[0091] Methods and techniques useful for carrying out the invention are described, for example, in Ausubel, FM (ed.), Current Protocols in Molecular Biology, Volumes I-III (1997), Glover, ND, and Hames, BD, ed., DNA Cloning: A Practical Approach, Volumes I and II (1985), Oxford University Press, Freshney, RI (ed.), Animal Cell Culture-a practical approach, IRL Press Limited (1986), Watson, JD, et al., Recombinant DNA, Second Edition, CHSL Press (1992), Winnacker, EL, From Genes to Clones; NY, VCH Publishers (1987), Celis, J., ed., Cell Biology, Second Edition, Academic Press (1998), Freshney, RI, Culture of Animal Cells: A Manual of Basic Technique, second edition, Alan R. Liss, Inc., NY (1987).
[0092] The term "about" refers to a range of ±20% of the numerical value that follows it. In one embodiment, the term about refers to a range of ±10% of the numerical value that follows it. In one embodiment, the term about refers to a range of ±5% of the numerical value that follows it.
[0093] The term "antibody" is used in the broadest sense herein and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, and multispecific antibodies (e.g., bispecific antibodies), so long as the antibody structure exhibits the desired antigen-binding activity. For example, a natural IgG antibody is a heterotetrameric glycoprotein of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From the N-terminus to the C-terminus, each heavy chain has a variable domain (VH), also called a variable heavy domain or heavy chain variable region, followed by three constant heavy domains (CH1, CH2, and CH3). Similarly, from the N-terminus to the C-terminus, each light chain has a variable domain (VL), also called a variable light domain or light chain variable region, followed by a constant light (CL) domain.
[0094] In certain embodiments, at least one domain of the fusion polypeptide is an antibody fragment. The term "antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody that retains the ability to specifically bind to an antigen. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, single chain Fab (scFab), single chain variable fragment (scFv), and single domain antibody (dAb). For a review of certain antibody fragments, see Holliger and Hudson, Nature Biotechnology 23 (2005) 1126-1136.
[0095] In one embodiment, the antibody fragment is a Fab fragment, a Fab' fragment, a Fab'-SH fragment, or a F(ab')2 fragment, in particular a Fab fragment. Papain digestion of an intact antibody produces two identical antigen-binding fragments, so-called "Fab" fragments, each of which contains the heavy and light chain variable domains (VH and VL, respectively), as well as the light chain constant domain (CL) and the first constant domain (CH1) of the heavy chain. The term "Fab fragment" thus refers to an antibody fragment that contains a light chain containing a VL domain and a CL domain, and a heavy chain fragment containing a VH domain and a CH1 domain. Fab' fragments differ from Fab fragments only by the addition of residues at the carboxy terminus of the CH1 domain that contain one or more cysteines from the antibody hinge region. Fab'-SH is a Fab' fragment in which the cysteine residue(s) of the constant domains bear a free thiol group. Pepsin treatment results in a F(ab')2 fragment with two antigen-binding sites (two Fab fragments) and part of the Fc region. See US Pat. No. 5,869,046 for a discussion of Fab and F(ab')2 fragments which contain salvage receptor binding epitope residues and have increased half-lives in vivo.
[0096] In another embodiment, the antibody fragment is a diabody, triabody, or tetrabody.A diabody is an antibody fragment that has two antigen binding sites, and can be bivalent or bispecific.See, for example, EP 404,097, WO1993 / 01161, Hudson et al., Nat.Med.9:129-134(2003), and Hollinger et al., Proc.Natl.Acad.Sci.USA 90:6444-6448(1993).Triabodies and tetrabodies are also described in Hudson et al., Nat.Med.9:129-134(2003).
[0097] In a further embodiment, the antibody fragment is a single chain Fab fragment. A "single chain Fab fragment" or "scFab" is a polypeptide consisting of an antibody heavy chain variable domain (VH), an antibody heavy chain constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL), and a peptide linker, the antibody domains and the linker having one of the following orders in the N-terminal to C-terminal direction: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1, or d) VL-CH1-linker-VH-CL. In particular, the peptide linker is a polypeptide of at least 30 amino acids, preferably 32 to 50 amino acids. The single chain Fab fragment is stabilized by a natural disulfide bond between the CL domain and the CH1 domain. In addition, these single-chain Fab fragments may be further stabilized by the creation of an interchain disulfide bond through the insertion of cysteine residues (e.g., at position 44 in the variable heavy chain and position 100 in the variable light chain according to the Kabat numbering).
[0098] In one embodiment, the antibody fragment is a Fab fragment with domain crossover. As used herein, the term "domain crossover" refers to deviations in domain sequence from the native sequence in that in the pair of an antibody heavy chain VH-CH1 fragment and its corresponding cognate antibody light chain, i.e. in the antibody binding arm (i.e. in the Fab fragment), at least one heavy chain domain is replaced by the corresponding light chain domain, and vice versa. There are three general types of domain crossovers: (i) crossovers of CH1 and CL domains, resulting in a domain crossover light chain with a VL-CH1 domain sequence and a domain crossover heavy chain fragment with a VH-CL domain sequence (or a full-length antibody heavy chain with a VH-CL-hinge-CH2-CH3 domain sequence); (ii) domain crossovers of VH and VL domains, resulting in a domain crossover light chain with a VH-CL domain sequence and a domain crossover heavy chain fragment with a VL-CH1 domain sequence; and (iii) domain crossovers of a complete light chain (VL-CL) and a complete VH-CH1 heavy chain fragment ("Fab crossover"), resulting in a domain crossover light chain with a VH-CH1 domain sequence and a domain crossover heavy chain fragment with a VL-CL domain sequence (all domain sequences listed above are in the N-terminal to C-terminal direction).
[0099] As used herein, the term "replaced with each other" with respect to corresponding heavy and light chain domains refers to the domain crossover described above.Therefore, when CH1 and CL domains "replaced with each other", the term refers to the domain crossover described under item (i) and the resulting heavy and light chain domain sequences.Therefore, when VH and VL "replaced with each other", the term refers to the domain crossover described under item (ii), and when CH1 and CL domains "replaced with each other" and VH1 and VL domains "replaced with each other", the term refers to the domain crossover described under item (iii). Bispecific antibodies containing domain crossovers have been reported, for example, in WO2009 / 080251, WO2009 / 080252, WO2009 / 080253, WO2009 / 080254 and Schaefer, W., et al., Proc. Natl. Acad. Sci USA 108 (2011) 11187-11192.
[0100] The fusion polypeptide according to the present invention can also comprise a Fab fragment, which comprises a domain crossover of the CH1 and CL domains mentioned under item (i) above, or a domain crossover of the VH and VL domains mentioned under item (ii). Fab fragments that specifically bind to the same antigen(s) are constructed to have the same domain sequence. Thus, when more than one Fab fragment with domain crossover is included in a multispecific antibody, the Fab fragment(s) specifically bind to the same antigen.
[0101] An "isolated" fusion polypeptide is one that is separated from components of its natural environment. In some embodiments, the fusion polypeptide is purified to greater than 95% or 99% purity, for example, as determined by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reverse-phase HPLC). For a review of methods for assessing antibody purity, see, for example, Flatman, S. et al., J. Chromatogr. B 848 (2007) 79-87.
[0102] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. Isolated nucleic acid includes a nucleic acid molecule contained within a cell that normally contains the nucleic acid molecule, but where the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
[0103] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies constituting the population are identical and / or bind the same epitope, with the exception of possible variant antibodies that contain, for example, natural mutations or arise during the manufacture of the monoclonal antibody preparation, which variants are generally present in small amounts. In contrast to polyclonal antibody preparations, which typically contain different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on the antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring the production of the antibody by any particular method. For example, the monoclonal antibodies used in accordance with the present invention may be produced by a variety of techniques, including, but not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci.
[0104] The "class" of an antibody refers to the type of constant domain or constant region carried by the heavy chain of the antibody. There are five major classes of antibodies, namely IgA, IgD, IgE, IgG, and IgM, some of which can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, σ, ε, γ, and μ, respectively.
[0105] The term "N-linked oligosaccharides" refers to oligosaccharides that are attached to the peptide backbone at asparagine amino acid residues by an asparagine-N-acetylglucosamine bond. N-linked oligosaccharides are also called "N-glycans". All N-linked oligosaccharides have a common pentasaccharide core of Man3GlcNAc2. All the N-linked oligosaccharides differ in the presence of peripheral sugars such as N-acetylglucosamine, galactose, N-acetylgalactosamine, fucose, and sialic acid and in the number of branches (also called antennae). Optionally, the structure can also contain a core fucose molecule and / or a xylose molecule. N-linked oligosaccharides are attached to the nitrogen of an asparagine or arginine side chain. N-glycosylation motifs, i.e., N-glycosylation sites, contain the Asn-X-Ser / Thr consensus base sequence, where X is any amino acid except proline. Thus, the amino acid residue at the N-glycosylation site can be any amino acid residue in the Asn-X-Ser / Thr consensus base sequence, where X is any amino acid except proline, hi one embodiment, the amino acid residue at the N-glycosylation site is Asn, Ser or Thr.
[0106] The term "O-linked oligosaccharides" refers to oligosaccharides that are attached to the peptide backbone at a threonine or serine amino acid residue. In one embodiment, the amino acid residue at the O-glycosylation site is Ser or Thr.
[0107] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have a similar structure, with each domain containing four conserved framework regions (FR) and three hypervariable regions (HVR). (See, for example, Kindt, TJ et al., Kuby Immunology, 6th ed., WH Freeman and Co., NY (2007), p. 91.) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated by screening a library of complementary VL or VH domains, respectively, using the VH or VL domain of an antigen-binding antibody. See, e.g., Portolano, S. et al., J. Immunol. 150 (1993) 880-887; Clackson, T. et al., Nature 352 (1991) 624-628).
[0108] As used herein, the term "post-translational modification" generally refers to a modification made to a polypeptide after translation. A non-limiting example of a post-translational modification is the attachment of a functional group, such as acetate, phosphate, lipid, or carbohydrate, to a polypeptide within a cell (i.e., in vivo).
[0109] More specifically, the term "post-translational modification" refers to the covalent modification of amino acid residues in a polypeptide after biosynthesis. Post-translational modifications can occur on the amino acid side chains by modifying existing functional groups or by introducing new functional groups. Known post-translational modifications of different proteinogenic amino acids are e.g. Ala: N-acetylation Arg: Deimination, methylation Asn: deamidation, N-linked glycosylation Asp:isomerization Cys: disulfide bond formation, oxidation, N-acetylation Gln: Cyclization Glu: cyclization, gamma carboxylation Gly: N-myristoylation, N-acetylation His: phosphorylation Lys: acetylation, ubiquitination, methylation, hydroxylation Met: N-acetylation, oxidation Pro: Hydroxylation followed by further modification Ser: phosphorylation, O-linked glycosylation Thr: phosphorylation, O-linked glycosylation, N-acetylation Trp: Oxidation Tyr: phosphorylation Val:N-acetylation It is.
[0110] As used herein, the term "glycosylation" refers to the covalent attachment of one or more carbohydrate moieties to an amino acid residue in a polypeptide. Typically, glycosylation is a post-translational event that can occur within the intracellular environment of a cell or a cell extract. The term glycosylation includes, for example, the addition of one or more carbohydrate moieties at a consensus site for glycosylation. One example of glycosylation encompasses the addition of one or more xylose residues to a polypeptide. For example, a consensus base sequence for xylose addition includes the sequence [D / E GSG D / E]. The term "O-glycosylation" refers to the covalent attachment of one or more carbohydrate moieties to an oxygen atom of the side chain of an amino acid residue in a polypeptide, such as the oxygen of a serine or threonine.
[0111] The term "phosphorylation" refers to a phosphate group (PO 4 ) to an amino acid residue in a polypeptide. Typically, phosphorylation is a post-translational event that can occur within the intracellular environment of a cell or cell extract. The term phosphorylation includes, for example, the addition of a phosphate group to the free hydroxyl group of serine.
[0112] The homogeneity of polypeptide is important when the polypeptide is to be used therapeutically.Surprisingly, as demonstrated herein, it has been found that changing the amino acid sequence of the peptide linker in fusion polypeptide reduces or eliminates the post-translational modification at the C-terminus of the peptide linker.The reduction or even elimination of the modification added after translation improves the homogeneity of polypeptide.
[0113] As used herein, the term "polypeptide" refers to a polymer containing 10 or more (up to 650) naturally occurring amino acid residues joined to each other through peptide bonds.
[0114] The term "amino acid" as used herein includes alanine (Ala (three letter code) or A (single letter code)), arginine (Arg or R), asparagine (Asn or N), aspartic acid (Asp or D), cysteine (Cys or C), glutamine (Gln or Q), glutamic acid (Glu or E), glycine (Gly or G), histidine (His or H), isoleucine (Ile or I), leucine (Leu or L), lysine (Lys or K), methionine (Met or M), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T), tryptophan (Trp or W), tyrosine (Tyr or Y), and valine (Val or V).
[0115] As used herein, the term "peptide linker" refers to a synthetic amino acid sequence that connects or links two polypeptide sequences, e.g., fuses two polypeptide domains together. Moreover, the peptide linker itself refers to a third domain. Thus, a fusion polypeptide comprising a peptide linker according to the present invention comprises at least three domains, namely a first (first polypeptide) domain, a second (peptide linker) domain, and a third (second polypeptide) domain. As used herein, the term "synthetic" refers to an amino acid sequence that is not naturally occurring. Thus, in one embodiment, the peptide linker according to the present invention is a synthetic peptide linker.
[0116] The peptide linker of the invention connects two amino acid sequences via a peptide bond. In one embodiment of this aspect of the invention, the peptide linker of the invention connects a first biologically active polypeptide (first domain) to a second polypeptide (third domain) in a linear sequence. In another embodiment of this aspect of the invention, the peptide linker connects two biologically active polypeptides.
[0117] In the context of a fusion polypeptide, "linear sequence" or "sequence" refers to the order of amino acids in a fusion polypeptide in the direction from amino terminus to carboxyl terminus (N→C terminal direction), where adjacent residues in the sequence are contiguous in the primary structure of the fusion polypeptide.
[0118] As used herein, the terms "coupled," "linked," "fused," or "fusion" can be used interchangeably. These terms refer to the joining together of two or more polypeptides or domains by recombinant means. As used herein, the terms "genetically fused," "genetically linked," or "genetic fusion" refer to the colinear covalent linkage or covalent attachment of two or more polypeptides via their individual peptide backbones via recombinant expression of a single nucleic acid molecule encoding the fusion polypeptide in a eukaryotic cell. Such a genetic fusion results in the expression of a single, contiguous genetic sequence. A preferred genetic fusion is in-frame, i.e., two or more open reading frames (ORFs) are fused to form a continuous, longer ORF in a manner that maintains the correct reading frame of the original ORFs. Thus, the resulting recombinant fusion polypeptide is a single polypeptide that contains two or more polypeptide domains that correspond to the polypeptides encoded by the original ORFs (these segments are not naturally coupled to each other).
[0119] The peptide linkers of the present invention differ from conventional Gly / Ser (GS) peptide linkers in the art in that the presently claimed peptide linkers lack at least a C-terminal serine amino acid residue and in that the next subsequent amino acid residue cannot be a serine, threonine or proline amino acid residue.
[0120] As used herein, the term "gly-ser linker" or "GS peptide linker" refers to a polypeptide consisting of glycine and serine residues. An exemplary gly / ser peptide linker has the amino acid sequence (Gly 4 Ser) n In one embodiment of all aspects of the invention, the peptide linker comprises or consists of a GS peptide linker having one or more amino acid substitutions, deletions, and / or additions and lacking a C-terminal serine residue.
[0121] In one embodiment of this aspect of the invention, the fusion polypeptide of the invention is a "chimeric" polypeptide. Such a chimeric fusion polypeptide comprises a first amino acid sequence (first domain) linked by a peptide linker (second domain) according to the invention to a second amino acid sequence (third domain) that is not naturally linked in nature. The amino acid sequences of the first and third domain polypeptides, which can be present in separate proteins or can be present in the same protein but separate from each other, come together in the fusion polypeptide in a new arrangement. Chimeric fusion polypeptides can be created, for example, by creating and translating a polynucleotide in which the domains are encoded in the desired relationship. Exemplary chimeric fusion polypeptides include fusion polypeptides that include peptide linkers of the invention.
[0122] A fusion polypeptide comprising a peptide linker of the invention can be either monomeric or polymeric. For example, in one embodiment, a fusion polypeptide of the invention is a dimer or tetramer.
[0123] In one embodiment of this aspect of the invention, a dimer of a fusion polypeptide of the invention is a homodimer comprising two identical monomeric fusion polypeptides of the invention.
[0124] In another embodiment of this aspect of the invention, the dimer of the fusion polypeptide of the invention is a heterodimer comprising two non-identical monomeric subunits, at least one of which is a fusion polypeptide according to the invention.
[0125] In another embodiment of this aspect of the invention, the tetramer of the fusion polypeptide of the invention is a heterotetramer comprising at least three non-identical monomeric subunits, at least one of which is a fusion polypeptide according to the invention.
[0126] In addition to including one or more peptide linkers according to the present invention, in certain embodiments, a fusion polypeptide can include one or more conventional GS peptide linkers at other positions within the fusion polypeptide.
[0127] The fusion polypeptide according to the present invention comprises at least one biologically active moiety. A biologically active moiety refers to a moiety that can localize or target a molecule to a desired site or cell, perform a function, or perform an action or reaction in a biological context. For example, the term "biologically active moiety" refers to a biologically active molecule or a portion thereof that binds to a component of a biological system (e.g., a protein in serum or on the surface of a cell or in a cell matrix) and that binding results in a biological effect (e.g., as measured by a change in the binding active moiety and / or component (e.g., cleavage of the binding active moiety and / or component, transmission of a signal, or enhancement or inhibition of a biological response in a cell or subject)).
[0128] Exemplary biologically active moieties include, for example, antigen-binding fragments of antibody molecules or portions thereof (e.g., F(ab), scFv, VH domain, or VL domain) (e.g., to act as a targeting moiety or to confer, induce, or block a biological response), ligand-binding portions of receptors or receptor-binding portions of ligands, and Fc region polypeptides, complete Fc regions, scFc domains, enzymes, etc. In addition, as used herein, the term "biologically active moiety" includes moieties that may not have activity when present alone, e.g., in monomeric form, but that have biological activity when paired with a second moiety in the context of a dimeric molecule.
[0129] In one embodiment of the aspects of the invention, the fusion polypeptide of the invention comprises a binding site in at least one of its fusion domains, or the binding site is obtained by fusion of domains in the fusion polypeptide. The term "binding domain" or "binding site" as used herein refers to a portion, region, or site of a polypeptide that mediates specific interaction with a target molecule (e.g., an antigen, a ligand, a receptor, a substrate, or an inhibitor). Exemplary binding domains include antigen binding sites (e.g., VH or VL domains or pairs thereof) or molecules (e.g., antibodies) that contain such binding sites, receptor binding domains of ligands, ligand binding domains of receptors, or catalytic domains.
[0130] In one embodiment of this aspect of the invention, the fusion polypeptide comprises (has) at least one binding domain that specifically binds to a target. In one embodiment of this aspect of the invention, the binding domain comprises or consists of an antigen binding site (e.g., a variable heavy and a variable light domain, or at least six CDRs from an antibody, or an isolated VH or VL or at least a functional portion thereof comprising only three CDRs). In one embodiment of this aspect of the invention, the binding domain functions as a targeting moiety.
[0131] In one embodiment of this aspect of the invention, the fusion polypeptide is a modified antibody chain or modified antibody. As used herein, the terms "modified antibody chain" and "modified antibody" include synthetic forms of antibody chains or antibodies that are altered to be non-natural, for example, by changing the structure, sequence, or number of natural domains. For example, heavy chain molecules linked to scFv molecules and the like. In addition, the term "modified antibody" includes multivalent forms of antibodies (e.g., antibodies that bind to three or more copies of the same antigen, such as trivalent, tetravalent, etc.).
[0132] In one embodiment of all aspects of the invention, the fusion polypeptide comprises an Fc region, or a domain thereof, or an Fc region polypeptide.
[0133] The term "antibody-dependent cellular cytotoxicity (ADCC)" refers to the function mediated by Fc receptor binding and the lysis of target cells in the presence of effector cells by the antibodies reported herein. In one embodiment, ADCC is measured by treating a preparation of CD19-expressing red blood cells (e.g., K562 cells expressing recombinant human CD19) with an antibody comprising the fusion polypeptide reported herein in the presence of effector cells, such as monocytes or NK (natural killer) cells, freshly isolated PBMCs (peripheral blood mononuclear cells) or effector cells purified from buffy coats. Target cells are labeled with 51Cr and then incubated with the antibody. The labeled cells are incubated with effector cells and the supernatant is analyzed for released 51Cr. Controls include incubation of target endothelial cells with effector cells but not with the antibody comprising the fusion polypeptide. The ability of an antibody to induce the early steps of mediating ADCC is examined by measuring the binding of the antibody to Fcγ receptor expressing cells, such as cells recombinantly expressing FcγRI and / or FcγRIIA or NK cells (which inherently express FcγRIIIA). In one embodiment, binding to FcγR on NK cells is measured.
[0134] "Effector function" refers to the biological activities attributable to the Fc region of an antibody, which vary depending on the class of antibody. Examples of antibody effector functions include C1q binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, down-regulation of cell surface receptors (e.g., B cell receptors), and B cell activation.
[0135] Fc receptor binding-dependent effector functions can be mediated by the interaction of the Fc region of an antibody with Fc receptors (FcRs), which are specialized cell surface receptors on hematopoietic cells. Fc receptors belong to the immunoglobulin superfamily and have been shown to mediate both the removal of antibody-coated pathogens by phagocytosis of immune complexes and the lysis of red blood cells and various other cellular targets (e.g., tumor cells) coated with the corresponding antibodies through antibody-dependent cellular cytotoxicity (ADCC) (see, e.g., Van de Winkel, JG and Anderson, CL, J. Leukoc. Biol. 49 (1991) 511-524). FcRs are defined by their specificity for immunoglobulin isotypes. The Fc receptor for IgG antibodies is called FcγR. Fc receptor binding is described, for example, in Ravetch, JV and Kinet, JP, Annu. Rev. Immunol. 9 (1991) 457-492, Capel, PJ, et al., Immunomethods 4 (1994) 25-34, de Haas, M., et al., J. Lab. Clin. Med. 126 (1995) 330-341, and Gessner, JE, et al., Ann. Hematol. 76 (1998) 231-248.
[0136] Cross-linking of receptors for the Fc region of IgG antibodies (FcγR) elicits a wide variety of effector functions, including phagocytosis, antibody-dependent cellular cytotoxicity, and release of inflammatory mediators, as well as regulation of immune complex clearance and antibody production. In humans, three classes of FcγR have been characterized:
[0137] FcγRI (CD64) binds monomeric IgG with high affinity and is expressed on macrophages, monocytes, neutrophils and eosinophils. Modification of the Fc region IgG at at least one of the amino acid residues E233-G236, P238, D265, N297, A327 and P329 (numbering according to the EU index of Kabat) reduces binding to FcγRI. IgG2 residues at positions 233-236 substituted into IgG1 and IgG4 reduce binding to FcγRI by 10.3 2-fold reduction in the human monocyte response to antibody-sensitized erythrocytes and abolished the human monocyte response to antibody-sensitized erythrocytes (Armour, KL, et al., Eur. J. Immunol. 29 (1999) 2613-2624).
[0138] FcγRII (CD32) binds complexed IgG with moderate to low affinity and is widely expressed. This receptor can be divided into two subtypes, FcγRIIA and FcγRIIB. FcγRIIA is found on many cells involved in killing (e.g., macrophages, monocytes, neutrophils) and appears to be able to activate the killing process. FcγRIIB appears to play a role in inhibitory processes and is found on B-cells, macrophages, as well as mast cells and eosinophils. On B cells, FcγRIIB appears to function to suppress further immunoglobulin production and isotype switching, for example to the IgE class. On macrophages, FcγRIIB acts to suppress phagocytosis mediated via FcγRIIA. On eosinophils and mast cells, type B can help suppress activation of these cells via binding of IgE to its distinct receptor. Reduced binding to FcγRIIA is observed for antibodies comprising an IgG Fc region with mutations in at least one of amino acid residues E233 to G236, P238, D265, N297, A327, P329, D270, Q295, A327, R292, and K414 (numbering according to the EU index as per Kabat).
[0139] FcγRIII (CD16) binds IgG with moderate to low affinity and exists as two types. FcγRIIIA is found on NK cells, macrophages, eosinophils, and some monocytes and T cells, and mediates ADCC. FcγRIIIB is abundantly expressed on neutrophils. Reduced binding to FcγRIIIA is observed, for example, for antibodies that contain an IgG Fc region with mutations at at least one of the amino acid residues E233-G236, P238, D265, N297, A327, P329, D270, Q295, A327, S239, E269, E293, Y296, V303, A327, K338, and D376 (numbering according to the EU index of Kabat).
[0140] Mapping of the binding sites on human IgG1 for Fc receptors, the mutation sites described above, and methods for measuring binding to FcγRI and FcγRIIA are described in Shields, RL, et al., J. Biol. Chem. 276 (2001) 6591-6604.
[0141] An "effective amount" of an agent, e.g., a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic or prophylactic result.
[0142] The term "Fc receptor" as used herein refers to an activating receptor characterized by the presence of a cytoplasmic ITAM sequence associated with the receptor (see, e.g., Ravetch, JV and Bolland, S., Annu. Rev. Immunol. 19 (2001) 275-290). Such receptors are FcγRI, FcγRIIA and FcγRIIIA. The term "no FcγR binding" refers to the binding of the antibodies reported herein to NK cells at an antibody concentration of 10 μg / ml that is 10% or less than that observed for the anti-OX40L antibody LC.001 reported in WO2006 / 029879.
[0143] The term "Fc region" is used herein to define the C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. An Fc region is a dimer of two Fc region polypeptides.
[0144] The Fc region of an antibody is directly involved in complement activation, C1q binding, C3 activation, and Fc receptor binding. The effect of an antibody on the complement system depends on certain conditions, but binding to C1q is caused by a defined binding site in the Fc region. Such binding sites are known in the state of the art and are described, for example, in Lukas, TJ, et al., J. Immunol. 127 (1981) 2555-2560; Brunhouse, R. and Cebra, JJ, Mol. Immunol. 16 (1979) 907-917; Burton, DR, et al., Nature 288 (1980) 338-344; Thommesen, JE, et al., Mol. Immunol. 37 (2000) 995-1004; Idusogie, EE, et al., J. Immunol. 164 (2000) 4178-4184; Hezareh, M., et al., J. Virol. 75 (2001) 12161-12168; Morgan, A., et al., Immunology 86 (1995) 319-324, and in European Patent No. 0307434. Such binding sites are, for example, L234, L235, D270, N297, E318, K320, K322, P331 and P329 (numbering according to the EU index of Kabat). Antibodies of the subclasses IgG1, IgG2 and IgG3 usually exhibit complement activation, C1q binding and C3 activation, whereas IgG4 does not activate the complement system, does not bind C1q and does not activate C3.
[0145] "Antibody Fc region" is a term well known to those skilled in the art and is defined based on papain cleavage of an antibody. In one embodiment, the Fc region is a human Fc region. In one embodiment, the Fc region is of the human IgG4 subclass, comprising the mutations S228P and / or L235E (numbering according to EU index of Kabat). In one embodiment, the Fc region is of the human IgG1 subclass, comprising the mutations L234A, L235A, and optionally P329G (numbering according to EU index of Kabat).
[0146] As used herein, the term "Fc region polypeptide" refers to a portion of a single immunoglobulin heavy chain beginning in the hinge region immediately upstream of the papain cleavage site of the antibody (i.e., residue 216 of IgG, with the first residue of the heavy chain constant region being 114) and ending at the C-terminus. Thus, a complete Fc region polypeptide includes at least the hinge domain, the CH2 domain, and the CH3 domain. As used herein, the term "Fc region" refers to a dimerized Fc region polypeptide similar to the Fc region of a native antibody (e.g., made in a traditional two polypeptide chain format or as a single chain Fc region).
[0147] As used herein, the term "Fc-region polypeptide portion" includes an amino acid sequence of an Fc-region polypeptide or an amino acid sequence derived from an Fc-region polypeptide. In certain embodiments, the Fc-region polypeptide portion includes at least one of a hinge (e.g., upper, middle, and / or lower hinge region) domain, a CH2 domain, a CH3 domain, a CH4 domain, or a variant, portion, or fragment thereof. In other embodiments, the Fc-region polypeptide portion includes a complete Fc-region polypeptide (i.e., a hinge domain, a CH2 domain, and a CH3 domain). In one embodiment, the Fc-region polypeptide portion includes a hinge domain (or a portion thereof) fused to a CH3 domain (or a portion thereof). In another embodiment, the Fc-region polypeptide portion includes a CH2 domain (or a portion thereof) fused to a CH3 domain (or a portion thereof). In another embodiment, the Fc-region polypeptide portion consists of a CH3 domain or a portion thereof. In another embodiment, the Fc-region polypeptide portion consists of a hinge domain (or a portion thereof) and a CH3 domain (or a portion thereof). In another embodiment, the Fc-region polypeptide portion consists of a CH2 domain (or a portion thereof) and a CH3 domain. In another embodiment, the Fc region polypeptide portion consists of a hinge domain (or portion thereof) and a CH2 domain (or portion thereof). In one embodiment, the Fc region polypeptide portion lacks at least a portion of the CH2 domain (e.g., all or part of the CH2 domain).
[0148] In one embodiment, the Fc region polypeptide comprises at least a portion of an Fc region known in the art to be required for FcRn binding, referred to herein as a neonatal receptor (FcRn) binding partner. An FcRn binding partner is a molecule or portion thereof that can be specifically bound by an FcRn receptor, resulting in active transport of the FcRn binding partner by the FcRn receptor. Specific binding refers to two molecules that form a complex that is relatively stable under physiological conditions. Specific binding is characterized by high affinity and low to moderate capacity, as distinguished from nonspecific binding, which usually has low affinity with moderate to high capacity.
[0149] Typically, binding occurs with an affinity constant KA of 10 6 M -1 When it is higher, or more preferably 10 8 M -1 When it is higher it is considered specific.
[0150] FcRn receptors have been isolated from several mammalian species, including humans. The sequences of human FcRn, monkey FcRn, rat FcRn, and mouse FcRn are known (Storey, et al., J. Exp. Med. 180 (1994) 2377). The FcRn receptor binds IgG (but not other immunoglobulin classes such as IgA, IgM, IgD, IgE) at a relatively low pH, actively transports the IgG across the cell in the direction from the lumen to the serosal membrane, and then releases the IgG at the relatively high pH found in the interstitial fluid.
[0151] FcRn binding partners include molecules to which the FcRn receptor can specifically bind, including whole IgG, the Fc region of IgG, and other fragments that contain the complete binding region of the FcRn receptor. The portion of the Fc region of IgG that binds to the FcRn receptor has been described based on X-ray crystallography (Burmeister et al. Nature 372 (1994) 379). The main contact area between Fc and FcRn is near the junction of the CH2 and CH3 domains. All of the Fc-FcRn contacts are within a single Ig heavy chain polypeptide. FcRn binding partners include whole IgG, the Fc region of IgG, a single Fc region polypeptide, and other fragments of IgG that contain the complete binding region of FcRn. The major contact sites include amino acid residues 248, 250-257, 272, 285, 288, 290-291, 308-311, and 314 in the CH2 domain and amino acid residues 385-387, 428, and 433-436 in the CH3 domain.
[0152] The fusion polypeptide of the present invention comprises at least one peptide linker of the present invention. In one embodiment, the fusion polypeptide comprises 1-10 peptide linkers. In one embodiment, two or more peptide linkers are present in the fusion polypeptide of the present invention. In another embodiment, the fusion polypeptide of the present invention comprises 1, 2, 3, or 4 peptide linkers of the present invention.
[0153] A peptide linker of the invention can occur once at a given position or can occur multiple times at different positions within the same fusion polypeptide.
[0154] The peptide linkers of the present invention are modified from those in the art such that the C-terminal serine amino acid is removed or replaced by a glycine residue, with the proviso that the next subsequent amino acid residue from the fusion polypeptide is not a serine, threonine or proline amino acid residue.
[0155] The peptide linkers of the present invention can be of various lengths. In one embodiment, the peptide linkers of the present invention are about 6 to about 75 amino acids in length. In another embodiment, the peptide linkers of the present invention are about 6 to about 50 amino acids in length. In another embodiment, the peptide linkers of the present invention are about 10 to about 40 amino acids in length. In another embodiment, the peptide linkers of the present invention are about 15 to about 35 amino acids in length. In another embodiment, the peptide linkers of the present invention are about 15 to about 20 amino acids in length. In another embodiment, the peptide linkers of the present invention are about 15 amino acids in length.
[0156] The position(s) of the peptide linker of the present invention can vary depending on the domains of the fusion polypeptide to which it connects. Although different embodiments of fusion polypeptides comprising peptide linkers are disclosed herein, it will be understood that the peptide linker can be placed at least wherever a peptide linker is currently placed in a recombinant fusion polypeptide. Peptide linkers are so frequently used in protein engineering that they have become standard building blocks in synthetic biology.
[0157] Some examples of current art-recognized uses for peptide linkers include scFv molecules (Freund et al., FEBS 320 (1993) 97), single-chain immunoglobulin molecules (Shun et al., Proc. Natl. Acad. Sci. USA 90 (1993) 7995), minibodies (Hun et al., Cancer Res. 56 (1996) 3055), CH2 domain deleted antibodies (Mueller et al., Proc. Natl. Acad. Sci. USA 87 (1990) 5702), single-chain bispecific antibodies (Schertz et al., Cancer Res. 65 (2005) 2882), full-length IgG-like bispecific antibodies (Marvin et al., Acta Pharm. Sin. 26 (2005) 649; Michelson et al., MAbs 1 (2009) 128; Routt et al., Prot. Eng. Des. Sell. 23 (2006) 221), scFv fusion proteins (Degree et al., Brit. J. Canc. 86 (2002) 811), the development of protein fragment complementation assays (Remy et al., BioTechniques 42 (2008) 137), and in scFc molecules (WO 2008 / 143954).
[0158] The peptide linker can be attached to the N-terminus or C-terminus (or both) of the polypeptide that is used to fuse it to another polypeptide.
[0159] In another embodiment, the peptide linkers of the invention can be used to genetically fuse two biologically active polypeptides (each of which is a domain), where each polypeptide has only one biological activity.
[0160] In another embodiment, a peptide linker of the invention is used to fuse two polypeptides to one another, where neither polypeptide has biological activity alone, but when genetically fused, is biologically active.
[0161] For example, in one embodiment, a peptide linker of the invention can be used to genetically fuse a VH and a VL in an scFv molecule as follows: ALB, where A is a VH or VL, B is a VH or VL, and L is a peptide linker according to the invention, or ALBL, where A is a VH or VL, B is a VH or VL, and L is a peptide linker according to the invention.
[0162] In another embodiment, a peptide linker can be used to genetically fuse a biologically active polypeptide to an entire Fc region, an Fc region polypeptide, an Fc region polypeptide portion, or an scFc region as follows: CL-Fc, where C is a biologically active polypeptide, L is a peptide linker according to the invention, and Fc is an Fc region (e.g., single chain or two conventional polypeptide chains), an Fc region polypeptide, an Fc region polypeptide portion, or an scFc region. For example, in one embodiment, C comprises an scFv molecule (e.g., comprising VH-L-VL or VL-L-VH, and L is a peptide linker), and Fc consists of an Fc region polypeptide (hinge-CH2-CH3 domains) or an scFc region, thus forming an scFv-Fc fusion protein or an scFv-scFc fusion protein. In another embodiment, C comprises an scFv molecule (e.g., VH-L-VL or VL-L-VH, where L is a peptide linker and Fc is a CH3 domain, thus forming a minibody. In another embodiment, C comprises two tandem scFv molecules and an Fc region polypeptide portion that is a CH3 domain, thereby forming a tetravalent minibody.
[0163] Tetravalent minibodies can also be formed using the following format: ALBL-Fc-LALB, where A and B are each one of a VH or VL domain, L is a peptide linker according to the invention, and Fc is a CH3 domain or an scFc region.
[0164] In another embodiment, the fusion polypeptide of the invention can have the following format: DLALB, where D is a complete antibody molecule, L is a peptide linker according to the invention, and A and B are VH or VL domains, respectively. Such a construct results in a C-terminal tetravalent antibody molecule.
[0165] In another embodiment, the fusion polypeptide of the invention can have the following format: ALBLD, where D is a complete antibody molecule, L is a peptide linker according to the invention, and A and B are VH or VL domains, respectively. Such a construct results in an N-terminal tetravalent antibody molecule. In such a construct, the ALB(scFv) portion of the molecule can be genetically fused to either the light or heavy chain variable region.
[0166] In another embodiment, the peptide linker of the present invention can be used to fuse the CH3 domain to the hinge region. In another embodiment, the peptide linker of the present invention can be used to fuse the CH3 domain to the CH1 domain. In yet another embodiment, the peptide linker according to the present invention can act as a spacer between the hinge region and the CH2 domain. A preferred location for the peptide linker according to the present invention is between the Fc region or Fc region polypeptide and the scFv or Fab.
[0167] Where more than one binding site is contained in a polypeptide, it will be understood that such molecules can be monospecific or multispecific, i.e., the binding sites can be the same or different.
[0168] Peptide linkers can be introduced into the polypeptide sequence using techniques known in the art. Modifications can be confirmed by DNA sequence analysis. Plasmid DNA can be used to transform host cells for stable production of the produced polypeptide.
[0169] The fusion polypeptides of the invention comprise at least one biologically active polypeptide (domain). Such polypeptides may be biologically active as single molecules or may require association with another polypeptide (e.g., when linked to a second polypeptide via a peptide linker or when present in a polypeptide dimer).
[0170] In one embodiment, the fusion polypeptides of the invention contain only one biologically active polypeptide (domain) (creating a molecule that is monomeric with respect to the biologically active polypeptide, but can be monomeric or dimeric with respect to the number of polypeptide chains). In another embodiment, the fusion polypeptides of the invention contain more than one biologically active polypeptide (domain), for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more biologically active polypeptides.
[0171] As used herein, the term "biologically active polypeptide" is not meant to include chemical effector moieties (e.g., toxic moieties, detectable moieties, and the like) that can be added to a polypeptide by chemical means.
[0172] In one embodiment of the invention, the biologically active polypeptide is operably linked to the N-terminus of the Fc region polypeptide or a portion thereof via a peptide linker according to the invention. In another embodiment, the biologically active polypeptide is operably linked to the C-terminus of the Fc region polypeptide via a peptide linker according to the invention.
[0173] In other embodiments, two or more biologically active polypeptides are linked in tandem to one another (e.g., via a peptide linker according to the invention). In one embodiment, a tandem array of biologically active polypeptides is operably linked to either the C-terminus or N-terminus of an Fc region polypeptide or portion thereof via a peptide linker according to the invention.
[0174] In one embodiment, a fusion polypeptide of the invention comprises at least one of an antigen binding site (eg, an antigen binding site of an antibody, antibody variant, or antibody fragment), a receptor binding portion of a ligand, or a ligand binding portion of a receptor.
[0175] In one embodiment, the biologically active polypeptide comprises an antigen binding site.
[0176] In certain embodiments, the fusion polypeptide of the present invention has at least one binding site specific for a target molecule that mediates a biological effect. In one embodiment, the binding site regulates cell activation or inhibition (e.g., by binding to a cell surface receptor and resulting in the transmission of an activating or inhibiting signal). In one embodiment, the binding site can initiate the transmission of a signal that leads to the death of a cell (e.g., by a cell signaling pathway, by complement fixation or exposure to a payload (e.g., a toxic payload) on the binding molecule), or regulate a disease or disorder in a subject (e.g., by mediating or promoting cell killing, by promoting the dissolution of a fibrin clot or promoting clot formation, or by regulating the amount of a biologically available substance (e.g., by enhancing or reducing the amount of a ligand such as TNF in a subject)). In another embodiment, the fusion polypeptide of the present invention has at least one binding site specific for an antigen, such as a cell surface antigen or a soluble antigen, that is targeted for reduction or elimination.
[0177] In another embodiment, binding of a fusion polypeptide of the invention to a target molecule (eg, an antigen) results in the reduction or elimination of the target molecule, for example, from a tissue or from the circulation.
[0178] In another embodiment, the fusion polypeptide has at least one binding site specific for a target molecule and can be used to detect the presence of the target molecule (e.g., to detect a contaminant or diagnose a condition or disorder).
[0179] In yet another embodiment, the fusion polypeptides of the invention contain at least one binding site that targets the molecule to a specific site in a subject (eg, a tumor cell, an immune cell, or a blood clot).
[0180] In certain embodiments, the fusion polypeptides of the invention can comprise two or more biologically active polypeptides. In one embodiment, the biologically active polypeptides are the same. In another embodiment, the biologically active polypeptides are different.
[0181] In certain detailed embodiments, the fusion polypeptides of the invention are multispecific, e.g., have at least one binding site that binds to a first molecule or epitope of a molecule and at least one second binding site that binds to a second molecule or second epitope of the first molecule. The multispecific binding molecules of the invention can include at least two binding sites. In certain embodiments, at least one binding site of the multispecific binding molecules of the invention is an antigen-binding region of an antibody or an antigen-binding fragment thereof (e.g., an antibody fragment or an antigen-binding fragment).
[0182] The following examples and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.
[0183] Example Overview: Fusion protein 1 HC1-F: Fusion protein 1 comprises two peptide linkers connecting the first non-IgG protein with the second non-IgG protein and the IgG heavy chain domain in the N-terminal to C-terminal direction. It was found to have phosphorylation of the C-terminal serine residue of TIFF2024164077000001.tif5128 (see Figures 1 to 8). Besides phosphorylation, xylosylation is also present. The phosphorylation results in a mass shift of +79 Da. The xylosylation results in a mass shift of +132 Da. Figure 1 shows the deconvoluted total mass spectrum of deglycosylated and reduced HC1-F. In addition to the expected HC1-F, another peak is seen indicating the presence of a strong +79 Da product variant of HC1-F. The presence of the modification in the linker of SEQ ID NO:9 was confirmed by subjecting a tryptic digest of HC1-F to LC-MS analysis. Figure 3 shows the (A) unmodified (elution time 36.5 min) and (B) +79.97 Da modified (elution time 37.6 min) tryptic glycine-serine linker peptides of HC1-F. Chromatograms (z=2 and 3) of ion current extraction (EIC) of TIFF2024164077000002.tif5128 are shown. Using ion trap MS / MS analysis with collision induced dissociation of the triply protonated unmodified and +79.97 Da modified trypsin digested glycine-serine linker peptides of HC1-F, as well as MS / MS analysis with electron transfer / high energy collision dissociation of the triply protonated modified peptide, it was confirmed that the additional 79.97 Da was localized to the C-terminal serine residue of the peptide linker (see FIG. 4). This was further confirmed by spiking synthetic polypeptides and enzymatic dephosphorylation (FIGS. 5 and 6). Digestion with thermolysin and LC-MS / MS allowed phosphorylation to be specifically localized to the glycine-serine linker I of fusion protein 1 (see FIG. 7 and FIG. 8).
[0184] To reduce the heterogeneity of the HC1-F fusion protein, the post-translational modification is removed by replacing the terminal serine residue of the peptide linker with a different residue, but not with proline or threonine, preferably with glycine, or by simply deleting said residue, provided that the next residue, i.e., the first residue of the polypeptide fused to the peptide linker, is also not a serine, threonine, or proline residue.
[0185] Fusion protein 2 HC2-F: Fusion protein 2 contains one peptide linker connecting the C-terminus of the antibody heavy chain with the truncated N-terminus of the antibody light chain. It was found that O-glycosylation of serine residues in TIFF2024164077000003.tif5128 was expressed (see Figures 9 to 13). Figure 9 shows O-xylosylation and O-glycosylation of HC2-F after reduction and analysis by UHR-QTOF-ESI-MS. In the ion extraction chromatogram of Figure 10 obtained from HC2-F, O-glycans were separated into peptides containing a glycine-serine linker. Identified in TIFF2024164077000004.tif5128. EThcD / HCD MS 2 was used to confirm the localization of GalNAc (+203 Da) and GalNAc-Gal-Neu5Ac (+656 Da) at the C-terminal serine residue of the GS-peptide linker (FIGS. 11 and 12). FIG. 13 shows the relative quantification of O-glycans of the HC peptide fragment of SEQ ID NO: 10 relative to the sum of unmodified and O-xylosylated peptides for HC2-F.
[0186] To reduce the heterogeneity of the HC2-F fusion protein, the terminal serine residue of the peptide linker is removed from post-translational modifications by replacing it with another residue, but not with proline or threonine, preferably with glycine, or by simply deleting the residue, provided that the next residue, i.e., the first residue of the polypeptide fused to the peptide linker, is also not a serine, threonine, or proline residue.
[0187] Fusion protein 3 LC3-F: Fusion protein 3 contains one peptide linker connecting the antibody light chain to the antibody Fc region. LC3-F contains the linker It was found that LC3-F was expressed by O-glycosylation of the threonine residue of TIFF2024164077000005.tif10132 (see Figures 14 to 16). Figure 14B shows the O-glycosylation of LC3-F produced in HEK cells after N-deglycosylation and the analysis of the intact protein by UHR-QTOF-ESI-MS. The modified GalNAc-Gal-2NeuAc (+948 Da) is quantified to be about 20%. Figure 14C shows the analysis of intact LC3-F and the intact protein after N-deglycosylation, desialylation, and the intact protein by UHR-QTOF-ESI-MS. FIG. 14D shows that O-glycosylation is localized to chain A of LC3-F after N-deglycosylation, desialylation, and reduced fusion protein 3 analysis by UHR-QTOF-ESI-MS.
[0188] Figure 15 shows the deconvoluted mass spectrum of an endoprotease digest (from Akkermansia muciniphila; OpeRATOR; Genovis) for LC3-F. Figure 16 shows the XIC for LC3-F after desialylation and tryptic digest with (upper XIC) or without (lower XIC) OpeRATOR protease. Fragment masses correspond to O-glycosylation of threonine residues in the hinge region. MS / MS of desialylated tryptic peptides digested with OpeRATOR protease localizing O-glycosylation to the N-terminal threonine residue (Figure 17).
[0189] To reduce the heterogeneity of the LC3-F fusion protein, the first residue of the polypeptide fused to the peptide linker, i.e., the threonine residue, is preferably replaced with glycine rather than with proline or serine, thereby removing the post-translational modification.
[0190] In the LC3-F mutant, the threonine residue at the end of the linker is omitted and replaced by a glycine residue, so that the linker has the amino acid sequence Included in the TIFF2024164077000006.tif4128. Figure 21 shows the mutant LC3-F after N-deglycosylation and the intact protein analyzed by UHR-QTOF-ESI-MS. Figure 22 shows the mutant LC3-F after N-deglycosylation, reduction, and analysis by UHR-QTOF-ESI-MS. There is no O-glycosylation in the mutant LC3-F.
[0191] Fusion protein 4 HC4-F: Fusion protein 4 contains a peptide linker connecting the non-IgG protein with the antibody Fc region. HC4-F contains the linker It was found that this is expressed by O-fucosylation of the serine residue of TIFF2024164077000007.tif5128 (see Figures 18 to 19). Figure 18 shows that O-fucosylation (+146 Da) is present in HC4-F after digestion with thermolysin, and peptide mapping (XIC) shows that the peptide Figure 19 shows that the modified synthetic peptide (27-310 nM) can be localized to HC4-F. The results of spiking TIFF2024164077000009.tif5128 into a tryptic digest are shown. The modified synthetic peptide is a modified HC4-F tryptic digest peptide. It co-elutes with TIFF2024164077000010.tif4128 and increases the area under the curve. XICs without spike (top) and with increasing levels of spike (bottom) are shown. O-fucosylation was localized to the terminal serine residue by LC-MS / MS tryptic peptide mapping (Figure 20). To reduce the heterogeneity of the HC4-F fusion protein, the post-translational modification is removed by replacing the terminal serine residue of the peptide linker with another residue, but not with proline or threonine, preferably with glycine, or by simply deleting the residue, provided that the next residue, i.e. the first residue of the polypeptide fused to the peptide linker, is also not a serine.
[0192] Specific embodiments: 1. Amino acid sequence GyX1 (SEQ ID NO: 4) wherein X1 can be any amino acid residue except serine, threonine, and proline; A fusion polypeptide comprising an amino acid sequence, wherein y is an integer between 3 and 25, inclusive.
[0193] 2. Amino acid sequence GyX1X2X3 (SEQ ID NO:5) wherein X1 can be any amino acid residue except serine, threonine, and proline; X2 and X3 can be, independently of each other, any amino acid residue; and 2. The fusion polypeptide of embodiment 1, comprising an amino acid sequence in which y is an integer between 3 and 25, inclusive.
[0194] 3. A fusion polypeptide according to any one of embodiments 1 to 2, wherein y is an integer between 4 and 20, inclusive.
[0195] 4. A fusion polypeptide according to any one of embodiments 1 to 3, wherein y is an integer between 5 and 15, inclusive.
[0196] 5. Amino acid sequence GnSGmX1X2X3 (SEQ ID NO: 2) wherein X1 can be any amino acid residue except serine, threonine, and proline; X2 and X3 can be, independently of each other, any amino acid residue; n=1, 2, 3 or 4, and A fusion polypeptide comprising an amino acid sequence, wherein m=3, 4 or 5.
[0197] 6. A fusion polypeptide according to any one of embodiments 1 to 5, comprising at least three domains, wherein each of the three domains, independently of the other two domains, is a polypeptide at least 10 amino acid residues in length; and The domains are coupled to each other via peptide bonds.
[0198] 7. The fusion polypeptide of embodiment 6, wherein the C-terminus of the first domain is conjugated to the N-terminus of the second domain via a peptide bond, and the C-terminus of the second domain is conjugated to the N-terminus of the third domain via a peptide bond.
[0199] 8. The fusion polypeptide of any one of embodiments 1 to 7, wherein the fusion polypeptide is a recombinant fusion polypeptide.
[0200] 9. The fusion polypeptide according to any one of embodiments 1 to 8, wherein said fusion polypeptide is produced in a eukaryotic cell.
[0201] 10. The fusion polypeptide of any one of embodiments 1 to 9, wherein said fusion polypeptide has no post-translational modification at S or X1 of SEQ ID NO: 01, or SEQ ID NO: 02, or SEQ ID NO: 04, respectively.
[0202] 11. The fusion polypeptide of any one of embodiments 1 to 10, wherein the linear fusion polypeptide has no post-translational modification at X1 of SEQ ID NO:01, or SEQ ID NO:02, or SEQ ID NO:04.
[0203] 12. The fusion polypeptide according to any one of embodiments 10 to 11, wherein said post-translational modification is phosphorylation (addition of a phosphate group) and / or glycosylation (addition of a carbohydrate moiety).
[0204] 13. The fusion polypeptide of embodiment 12, wherein said glycosylation is xylosylation (the carbohydrate moiety is xylose).
[0205] 14. The fusion polypeptide of embodiment 12, wherein said glycosylation is glucosylation (the carbohydrate moiety is glucose).
[0206] 15. The fusion polypeptide, comprising: GpSGnSGmX1X2X3 (SEQ ID NO: 6) A fusion polypeptide comprising: X1 is serine, threonine, or proline; X2 and X3 can be, independently of each other, any amino acid residue; n=1, 2, 3 or 4; p=n or p=1, 2, 3 or 4, and Fusion polypeptides, where m=3, 4 or 5. 15. The fusion polypeptide according to any one of embodiments 5 to 14, having reduced post-translational modifications at residues S and / or X1 compared to
[0207] 16. A fusion polypeptide according to any one of embodiments 5 to 15, wherein n=3 and m=3 or 4.
[0208] 17. A fusion polypeptide according to any one of embodiments 5 to 15, wherein n=3 and m=4.
[0209] 18. A fusion polypeptide according to any one of embodiments 5 to 15, wherein n=4 and m=4 or 5.
[0210] 19. A fusion polypeptide according to any one of embodiments 5 to 15, wherein n=4 and m=5.
[0211] 20. The fusion polypeptide has the amino acid sequence GpSGnSGmX1X2X3 (SEQ ID NO: 3) wherein X1 can be any amino acid residue except serine, threonine, and proline; X2 and X3 can be, independently of each other, any amino acid residue; n=1, 2, 3 or 4; m=3, 4, or 5, and 20. The fusion polypeptide according to any one of embodiments 1 to 19, comprising an amino acid sequence in which p=3 or 4.
[0212] 21. The fusion polypeptide according to any one of embodiments 1 to 20, wherein the fusion polypeptide further comprises an antibody Fc region polypeptide / at least one of the domains is an antibody Fc region polypeptide.
[0213] 22. The fusion polypeptide of any one of embodiments 6 to 21, wherein the first or / and the third domain is an antibody Fc region polypeptide.
[0214] 23. The fusion polypeptide according to any one of embodiments 1 to 22, wherein the fusion polypeptide further comprises a VH domain, a VL domain, an scFv, an scFab, a VH-CH1 pair, a VL-CL pair, a VH-CL pair, a VL-CH1 pair, a receptor or an extracellular domain thereof, a receptor binding portion of a ligand, an enzyme, a growth factor, an interleukin, a cytokine, or a chemokine / The fusion polypeptide according to any one of embodiments 2 to 18, wherein at least one domain of the fusion polypeptide is selected from the group consisting of a VH domain, a VL domain, an scFv, a VH-CH1 pair, a VL-CL pair, a VH-CL pair, a VL-CH1 pair, a receptor or an extracellular domain thereof, a receptor binding portion of a ligand, an enzyme, a growth factor, an interleukin, a cytokine, and a chemokine.
[0215] 24. The fusion polypeptide of any one of embodiments 1 to 23, wherein the fusion polypeptide is monomeric.
[0216] 25. The fusion polypeptide of any one of embodiments 1 to 24, wherein the fusion polypeptide is a linear fusion polypeptide.
[0217] 26. At least two polypeptides, at least one of which is a fusion polypeptide according to any one of embodiments 1 to 25. A polymeric molecule comprising:
[0218] 27. The multimeric molecule of embodiment 26, wherein said at least two polypeptides are coupled to each other by one or more disulfide bonds.
[0219] 28. The multimeric molecule according to any one of embodiments 26 to 27, wherein the multimeric molecule is an antibody.
[0220] 29. The multimeric molecule according to any one of embodiments 26 to 28, wherein said multimeric molecule is a bispecific antibody.
[0221] 30. The multimeric molecule according to any one of embodiments 26 to 29, further comprising at least one antibody light chain.
[0222] 31. The multimeric molecule according to any one of embodiments 26 to 30, further comprising at least one antibody heavy chain.
[0223] 32. A pharmaceutical composition comprising at least one fusion polypeptide according to any one of embodiments 1 to 25 or a multimeric molecule according to any one of embodiments 26 to 31, and optionally a pharma- ceutical acceptable carrier.
[0224] 33. A nucleic acid molecule encoding a fusion polypeptide according to any one of embodiments 1 to 26.
[0225] 34. The nucleic acid molecule of embodiment 33, wherein the nucleic acid molecule is in an expression cassette.
[0226] 35. The nucleic acid molecule according to any one of embodiments 34 to 35, wherein the nucleic acid molecule is in a vector.
[0227] 36. A set of nucleic acid molecules encoding the polypeptides of a multimeric molecule according to any one of embodiments 26 to 31.
[0228] 37. The set of nucleic acid molecules according to embodiment 36, wherein each of the nucleic acid molecules is in an expression cassette.
[0229] 38. A set of nucleic acid molecules according to any one of embodiments 36 to 37, wherein each of the nucleic acid molecules is in a vector.
[0230] 39. A set of nucleic acid molecules according to any one of embodiments 36 to 37, wherein the nucleic acid molecules are on the same vector.
[0231] 40. A set of nucleic acid molecules according to any one of embodiments 36 to 37, wherein the nucleic acid molecules are on different vectors.
[0232] 41. A set of nucleic acid molecules according to any one of embodiments 36 to 37, wherein the nucleic acid molecules are on two vectors.
[0233] 42. A eukaryotic cell comprising a nucleic acid molecule according to embodiment 33 or a set of nucleic acid molecules according to embodiment 36.
[0234] 43. Amino acid sequence GyX1 (SEQ ID NO: 4) wherein X1 can be any amino acid residue except serine, threonine, and proline; A peptide linker comprising an amino acid sequence, wherein y is an integer of 3 to 25, inclusive.
[0235] 44. Amino acid sequence GyX1X2X3 (SEQ ID NO:5) wherein X1 can be any amino acid residue except serine, threonine, and proline; X2 and X3 can be, independently of each other, any amino acid residue; and A peptide linker comprising an amino acid sequence, wherein y is an integer of 3 to 25, inclusive.
[0236] 45. A peptide linker according to any one of embodiments 43 to 44, wherein y is an integer between 4 and 20, inclusive.
[0237] 46. A peptide linker according to any one of embodiments 43 to 45, wherein y is an integer between 5 and 15, inclusive.
[0238] 47. Amino acid sequence GnSGmX1X2X3 (SEQ ID NO: 1) wherein X1 can be any amino acid residue except serine, threonine, and proline; X2 and X3 can be, independently of each other, any amino acid residue; n=1, 2, 3 or 4, and A peptide linker comprising an amino acid sequence, wherein m=3, 4 or 5.
[0239] 48. Amino acid sequence GpSGnSGmX1X2X3 (SEQ ID NO: 3) wherein X1 can be any amino acid residue except serine, threonine, and proline; X2 and X3 can be, independently of each other, any amino acid residue; n=1, 2, 3 or 4; m=3, 4, or 5, and A peptide linker comprising an amino acid sequence, where p=3 or 4.
[0240] 49. A fusion polypeptide according to any one of embodiments 47 to 48, wherein n=3 and m=3 or 4.
[0241] 50. A fusion polypeptide according to any one of embodiments 47 to 49, wherein n=3 and m=4.
[0242] 51. A fusion polypeptide according to any one of embodiments 47 to 48, wherein n=4 and m=4 or 5.
[0243] 52. A fusion polypeptide according to any one of embodiments 47 to 48 and 51, wherein n=4 and m=5.
[0244] 53. A method for producing a fusion polypeptide, comprising the steps of: - culturing the eukaryotic cell according to embodiment 42 under conditions in which the fusion polypeptide is expressed, and - recovering the fusion polypeptide from the eukaryotic cell or culture medium; Thereby producing a fusion polypeptide.
[0245] 54. A method for producing a fusion polypeptide having a reduced level of post-translational modification, comprising: - culturing a host cell according to embodiment 42 under conditions in which the fusion polypeptide is expressed, and recovering the fusion polypeptide from the eukaryotic cell or culture medium; Thereby producing a fusion polypeptide having a reduced level of post-translational modification.
[0246] 55. A method for producing a stabilized fusion polypeptide, comprising genetically engineering a fusion protein to include a peptide linker according to any one of embodiments 43 to 52, and expressing the fusion polypeptide by a eukaryotic cell, thereby producing a stabilized fusion polypeptide.
[0247] 56. A composition made by the method according to any one of embodiments 53 to 55.
[0248] 57. A method for treating a subject who would benefit from treatment with a fusion polypeptide according to any one of embodiments 1 to 25 or a multimeric molecule according to any one of embodiments 26 to 31, comprising administering a composition according to any one of embodiments 32 to 56 to a subject who would benefit from treatment with a fusion polypeptide according to any one of embodiments 1 to 25 or a multimeric molecule according to any one of embodiments 26 to 31.
[0249] 58. Use of a composition according to any one of embodiments 32 or 56 for the treatment of a disease or disorder.
[0250] 59. Use of a composition according to any one of claims 32 or 56 for the manufacture of a medicament.
[0251] 60. A fusion polypeptide according to any one of embodiments 1 to 25 or a multimeric molecule according to any one of embodiments 26 to 31 for use as a medicament.
[0252] 61. Use of a fusion polypeptide according to any one of embodiments 1 to 25 or a multimeric molecule according to any one of embodiments 26 to 31 in the manufacture of a medicament.
[0253] 62. A method for treating an individual in need thereof, comprising administering to said individual an effective amount of a fusion polypeptide according to any one of embodiments 1 to 25 or a multimeric molecule according to any one of embodiments 26 to 31. [Brief description of the drawings]
[0254] (FIG. 1) FIG. 1 shows the total mass measurement of a fusion protein containing an antibody heavy chain constant domain and a non-antibody polypeptide (HC1-F) transiently expressed in human embryonic kidney cells. The deconvoluted mass spectrum of deglycosylated and reduced HC1-F is shown. In addition to the expected HC1-F, another peak is seen indicating the presence of a strong +79 Da product variant of HC1-F. A less intense signal due to the +132 Da xylose product variant was also present. (Figure 2) Figure 2 illustrates a schematic diagram of HC1-F. HC1-F consists of two >10 kDa non-IgG proteins fused to an IgG heavy chain constant domain by two standard glycine-serine [(G4S)2] linkers I and II. (Figure 3) Figure 3 shows the tryptic glycine-serine linker peptide of (A) unmodified (elution time 36.5 min) and (B) +79.97 Da modified (elution time 37.6 min) of HC1-F. Chromatograms (z=2 and 3) of the ion current extraction (EIC) of TIFF2024164077000011.tif5128 are shown. Relative comparison of integrated EIC chromatograms quantified the modification to be 5.5% (including 1.1% of O-xylose). MA: manually integrated peaks, NL: normalized intensity level. (FIG. 4A) Figure 4 shows ion trap MS / MS data obtained by collision induced dissociation of (A) unmodified and (B) +79.97 Da modified trypsin digested glycine-serine linker peptide of HC1-F, as well as (C) MS / MS spectrum by electron transfer / high energy collision dissociation of the triply protonated modified polypeptide. The additional 79.97 Da is localized to the C-terminal serine residue. (Figure 4B) See legend to Figure 4A. (Figure 4C) See legend to Figure 4A. (FIG. 5) FIG. 5 shows the effect of spiking synthetic phosphopeptides into tryptic digests. Unmodified and +79.97 Da modified tryptic linker peptides of HC1-F. Ion current extraction chromatograms (z=2 and 3) of TIFF2024164077000012.tif5128 for (A) unspiked, (B) 0.5 μM, and (C) 1.0 μM spiked synthetic phosphopeptide. TIFF2024164077000013.tif5128 has been added. The spiked sample demonstrates an increase in the peak area of the phosphopeptides, giving correct identification of the modified tryptic peptides. NL: normalized intensity level. (FIG. 6) FIG. 6 shows the results of enzymatic dephosphorylation of the modified tryptic linker peptide of HC1-F with alkaline phosphatase. Unmodified and +79.97 Da modified tryptic linker peptide Ion current extraction chromatograms (z=2 and 3) of TIFF2024164077000014.tif5128 incubated with alkaline phosphatase (A) and without alkaline phosphatase (control reaction). Modified tryptic peptides were no longer detectable after enzymatic dephosphorylation. NL: normalized intensity level. (FIG. 7A) FIG. 7 shows that the specific phosphorylation is of the glycine-serine linker I. (A) Thermolysin-digested unmodified (elution time 12.5 min) and phosphorylated (elution time 13.5 min) glycine-serine linker I peptides of HC1-F. Ion current extraction chromatogram (EIC) (z=2) of TIFF2024164077000015.tif5128. Relative comparison of integrated EIC chromatograms quantified the modification to be 11.3%, including 1.4% with O-xylose in the GSG motif (data not shown). Orbitrap HCD-MS / MS data of doubly protonated unmodified and modified thermolysin-digested glycine-serine linker I peptides are shown in (B) and (C), respectively. The +79.97 Da modification is localized to the C-terminal serine residue. MA: manually integrated peaks, NL: normalized intensity levels. (Figure 7B) See legend to Figure 7A. (Figure 7C) See legend to Figure 7A. (FIG. 8A) Figure 8 shows linker phosphorylation of HC1-F stably expressed in Chinese hamster ovary cells. (A) Unmodified (elution time 15.6 min) and phosphorylated (elution time 16.85 min) thermolysin-digested glycine-serine linker I peptides. Extracted ion current (EIC) chromatogram (z=2) of TIFF2024164077000016.tif5128. The phosphorylated peptide was quantified to be 0.4%. (B) HCD-MS / MS data of the doubly protonated modified thermolysin digest peptides. MA: manually integrated peaks, NL: normalized intensity levels. (Figure 8B) See legend to Figure 8A. (Figure 9) Figure 9 shows O-xylosylation and O-glycosylation of fusion protein 2 (produced in CHO cells, HC2-F) after reduction and analysis by UHR-QTOF-ESI-MS. (Figure 10) Figure 10 was obtained using HC2-F. Major signals induced by Fc-N-glycans (retention times 16 min, 62-66 min). Peptides containing glycine-serine linkers O-glycans identified for TIFF2024164077000017.tif5128 (retention time 43–46 min). (FIG. 11) FIG. 11 shows MS / MS of peptide fragments containing O-glycosylation of FIG. 10 with O-glycans, and peptide identification for HC2-F. (FIG. 12) FIG. 12 shows the results of MS / MS for the peptide of SEQ ID NO: 10 for HC2-F. EThcD / HCD MS 2 Using this method, GalNAc (+203 Da) and GalNAc-Gal-Neu5Ac (+656 Da) could be localized to the C-terminal serine residue of the GS-peptide linker. In addition, several O-xylose hits (+132 Da) could be localized to other serine residues in the peptide linker. (FIG. 13) FIG. 13 shows the relative quantification of O-glycans of the HC peptide fragment of SEQ ID NO: 10 relative to the total of unmodified and O-xylosylated peptides for HC2-F. (FIG. 14A) FIG. 14A shows O-glycosylation of fusion protein 3 (LC3-F, produced in HEK cells) after analysis of the intact protein by UHR-QTOF-ESI-MS. FIG. 14B shows the deconvoluted mass spectrum of the N-deglycosylated intact protein containing LC3-F produced in HEK cells, FIG. 14C shows the deconvoluted mass spectrum of the N-deglycosylated and desialylated intact protein containing LC-3F, and FIG. 14D shows the deconvoluted mass spectrum of the N-deglycosylated and reduced LC3-F. The molecular masses determined for the N-deglycosylated intact protein or annotated variants of LC-3F are listed (annotation: B: +364.8 Da (GalNAc-Gal), +656.8 Da (GalNAc-Gal-Neu5Ac), +948.2 Da (GalNAc-Gal-2Neu5Ac), +1313.1 Da (2xGalNAc-Gal-Neu5Ac), +1602.2 Da (GalNAc-Gal-Neu5Ac and GalNAc-Gal-Neu5Ac). C: +365.7 Da (GalNAc-Gal), +731.0 Da (2xGalNAc-Gal) and chain A (C: +365.5 Da (GalNAc-Gal), +729.8 Da (2xGalNAc-Gal)). GalNAc (squares), Gal (circles), and Neu5Ac (diamonds). The modification GalNAc-Gal-2NeuAc (+948 Da) is quantified to be approximately 20%. (Figure 14B) See legend to Figure 14A. (Figure 14C) See legend to Figure 14A. (Figure 14D) See legend to Figure 14A. (FIG. 15) FIG. 15 shows the deconvoluted mass spectrum of the OpeRATOR digest for LC3-F. The fragment mass corresponds to O-glycosylation of the threonine residue in the hinge region. OpeRATOR is derived from Akkermansia muciniphila and expressed in E. coli. The enzyme contains a His tag and has a molecular weight of 42 kDa. (FIG. 16) FIG. 16 shows the XIC for LC3-F after desialylation and tryptic digests with (upper XIC) or without (lower XIC) OpeRATOR protease. O-glycosylation (+365.13 Da=GalNAc-Gal) is the following sequence (underlined): TIFF2024164077000018.tif11128, i.e., localized to the threonine residue at the C-terminus of the GS peptide linker (identified by peptide mapping (LC-MS / MS)). O-glycosylated tryptic peptide digested at the O-glycosylated threonine residue TIFF2024164077000019.tif11128 and unmodified tryptic peptides XIC of TIFF2024164077000020.tif11128 is shown. +59.01=carboxymethylation. (FIG. 17) FIG. 17 shows MS / MS of desialylated tryptic peptides digested with OpeRATOR protease localizing O-glycosylation (+365.13 Da=GalNAc-Gal) to the N-terminal threonine residue for LC3-F. +59.01=carboxymethylation. (FIG. 18) FIG. 18 shows that fusion protein 4 (HC4-F) after digestion with thermolysin had O-fucosylation (+146 Da), and peptide mapping (LC-MS / MS) revealed that the peptide TIFF2024164077000021.tif5128 shows that the XICs of modified (lower XIC, 2.06%) and unmodified (upper XIC) thermolysin digested peptide fragments are shown. (Figure 19-1) Figure 19 shows the activity of modified synthetic peptides (27-310 nM) for HC4-F. The results of spiking TIFF2024164077000022.tif5128 into a tryptic digest are shown. The modified synthetic peptide is a modified HC4-F tryptic digest peptide. It co-elutes with TIFF2024164077000023.tif4128, increasing the area under the curve. Shown are XICs with no spike (top) and increasing levels of spike (bottom). (Figure 19-2) See the explanation for Figure 19-1. (Figure 20-1) Figure 20 shows the MS / MS results of tryptic peptides for HC4-F, which localize O-fucosylation (+146 Da) to the C-terminal serine residue. (Figure 20-2) See the explanation for Figure 20-1. (FIG. 21-1) FIG. 21 shows mass spectra (upper: full scale, lower: zoom) of LC3-F mutants after N-deglycosylation and analysis of the intact protein by UHR-QTOF-ESI-MS. Amino acid sequence There is no O-glycosylation in the mutant of LC3-F with a linker containing TIFF2024164077000024.tif5128. (Figure 21-2) See the explanation for Figure 21-1. (Figure 22-1) Figure 22 shows mass spectra (upper: full scale, lower: zoom) of LC3-F mutants after N-deglycosylation and analysis of the reduced protein by UHR-QTOF-ESI-MS. Amino acid sequence There is no O-glycosylation in the mutant of LC3-F with a linker containing TIFF2024164077000025.tif5128. (Figure 22-2) See the explanation for Figure 22-1. EXAMPLES
[0255] Sample overview: Fusion protein 1 HC1-F: linker The serine residue in TIFF2024164077000026.tif5128 is phosphorylated (see Figures 1-8). Fusion protein 2 HC2-F: linker The serine residue in TIFF2024164077000027.tif5128 is O-glycosylated (see Figures 9-13). Fusion protein 3 LC3-F: linker The threonine residue in TIFF2024164077000028.tif10132 is O-glycosylated (see Figures 14-17). Fusion protein 4 HC4-F: linker The serine residue in TIFF2024164077000029.tif5128 is O-fucosylated (see Figures 18-20).
[0256] Mutant fusion protein 4 HC4-F: amino acid sequence The linker containing TIFF2024164077000030.tif5128 is free of O-glycosylation (see Figures 21-22).
[0257] Trypsin, thermolysin, neuraminidase, and alkaline phosphatase from bovine intestinal mucosa were ordered from Sigma-Aldrich.
[0258] Synthetic peptides (98% HPLC purity) were synthesized at Biosyntan GmbH.
[0259] PNGase F was obtained from Roche Diagnostics GmbH, Custom Biotech.
[0260] OpeRATOR protease was obtained from Genovis AB (Lund, Sweden) (OpeRATOR is an O-protease that digests proteins O-glycosylated at the N-terminus of the S / T glycosylation site; OpeRATOR requires the presence of O-glycans to exert its enzymatic activity). Example 1
[0261] enzymatic digest UHR-ESI-QTOF-MS The fusion proteins were deglycosylated with PNGase F (with or without neuraminidase), reduced in 100 mM TCEP, and desalted by HPLC on a Sephadex G25 5x250 mm column (Amersham Biosciences) using 40% acetonitrile with 2% formic acid (v / v) as the mobile phase. Total mass was measured by ESI-QTOF MS on a maXis 4G UHR-QTOF MS system (Bruker Daltonik) equipped with a TriVersa NanoMate source (Advion). Calibration was performed using ESI-L low concentration tuning mix (Agilent Technologies). To visualize the results, m / z spectra were converted to deconvoluted mass spectra using a software tool.
[0262] OpeRATOR Digest The fusion protein was N-deglycosylated with PNGase F, desialylated with neuraminidase, then reduced, denatured, and carboxymethylated, and finally digested with an O-glycan-specific endoprotease as indicated by the vendor (OpeRATOR, Genovis AB, Sweden). The digests were analyzed by UHR-ESI-QTOF-MS. Example 2
[0263] UPLC-MS / MS peptide mapping The fusion protein was denatured and reduced in 0.3 M Tris-HCl, pH 8, containing 6 M guanidine-HCl and 20 mM dithiothreitol (DTT) for 1 h at 37 °C. The fusion protein was then alkylated by adding 40 mM iodoacetic acid (C13:99%) (Sigma-Aldrich) and incubating at room temperature in the dark for 15 min. Excess iodoacetic acid was inactivated by adding an additional 20 mM DTT to the reaction mixture. The alkylated fusion protein was buffer exchanged using a NAP5 gel filtration column. The fusion protein was then proteolytically digested with trypsin in 50 mM Tris-HCl, pH 7.5 (with or without OpeRATOR protease) for 16 h at 37 °C. The reaction was stopped by adding formic acid to 0.4% (v / v). Thermolysin digestion was performed in 25 mM Tris-HCl, 1 mM CaCl 2 , pH 8.3 for 30 min at 25 °C and stopped by adding EDTA to 8 mM. Digested samples were stored at -80 °C and analyzed by UPLC-MS / MS using a NanoAcquity UPLC (Waters) coupled to a TriVersa NanoMate (Advion) and Orbitrap Elite mass spectrometer (Thermo Fisher Scientific). Approximately 2.4 μg of digested fusion protein was injected in a volume of 5 μL. Chromatographic separation was performed by reversed phase on an Acquity BEH300 C18 column, 1 × 150 mm, 1.7 μm, 300 Å (Waters) using a flow rate of 60 μL / min. Mobile phases A and B contained 0.1% (v / v) formic acid in UPLC grade water and acetonitrile, respectively. A column temperature of 50 °C was used, and a gradient of 1% to 40% mobile phase B over 90 min was applied, followed by a ramp to 99% mobile phase B in 2 min, with a 6 min re-equilibration step at 1% mobile phase B. Two injections of mobile phase A were performed between sample injections using a 50 min gradient to prevent carryover between samples. A TriVersa NanoMate was used to split the eluent post-column and deliver nanoliter flow fractions to the mass spectrometer.
[0264] High-resolution MS spectra were acquired using an Orbitrap mass spectrometer, allowing parallel detection of CID MS / MS fragments in the ion trap with dynamic exclusion (repeat count 1, exclusion time 15 s (±10 ppm)). The Orbitrap Fusion was used in data-dependent mode.
[0265] The MS settings were as follows: Full MS (AGC: 2 × 10 5 , resolution: 6×10 4 , m / z range: 300-2000, maximum injection time: 100 ms), MS / MS (AGC: 1×10 4 , maximum injection time: 100 ms, isolation width: 2 Da). The normalized collision energy was set to 35%, activation p: 0.25, isolation width: 2 Da.
[0266] For the method of acquiring only HCD MS / MS spectra, up to 20 HCD Orbitrap MS / MS spectra were acquired for the most abundant ions in an Orbitrap full MS scan. The AGC for the MS / MS experiments was 5 × 10 with a maximum injection time of 500 ms. 4 The normalized collision energy was set to 20%, and the HCD fragmentation ions were set to 15 × 10 3 Detection was performed in the Orbitrap with a resolution setting of 0.01 μg / mL. All other settings were as described for the method using only CID fragmentation.
[0267] The complementary EThcD method, based on HCD and ETD as data-dependent fragmentation techniques, involved full-scan MS acquired on an Orbitrap mass analyzer and parallel detection of ETD and HCD fragment ion spectra on an ion trap and an Orbitrap mass analyzer. A fixed cycle time was set for the full scan, using as many data-dependent MS / MS scans as possible.
[0268] Full MS: Same settings as for CID and HCD.
[0269] For HCD, the MS / MS settings were the same as listed above.
[0270] For ETD and MS / MS, the settings were as follows: reaction time 50 ms, ETD reagent target: 1 × 10 6 Maximum injection time: set to 200 ms. ETD supplemental activation was enabled. Supplemental activation collision energy was set to 25%. AGC target was set to 1 × 10 4 , precursor separation width was 2 Da, and maximum injection time was set to 250 ms.
[0271] Analysis of LC-MS / MS data and identification of post-translational modifications (PTMs) were performed using PEAKS studio 6.0 and 7.5 software (Bioinformatics Solutions Inc.) with the preprocessing option and PepFinder software (Thermo Fisher Scientific). Manual data interpretation and quantification were performed using XCalibur software (Thermo Fisher Scientific). Theoretical masses were calculated using GPMAW (Lighthouse data) and XICs were generated at the most intense isotope mass using a mass tolerance of 8 ppm. Example 3
[0272] Synthetic peptide spikes Based on the calculated amount of modified peptide, a certain amount of synthetic peptide was spiked into the tryptic digest. 2.4 μg of tryptic digest with or without spiked synthetic peptide was analyzed by LC-MS / MS as described above. Example 4
[0273] Enzymatic dephosphorylation Enzymatic dephosphorylation of the +79.97 Da modified tryptic linker peptide was performed by lyophilizing approximately 62 μg of the tryptic digest. The peptide was then resuspended in 25 μL of 100 mM Tris-HCl, 5 mM MnCl. 2The digested samples were stored at -80° C. MS analysis was performed as previously described.
[0274] It will be readily understood that the embodiments, as generally described herein, are exemplary. The presented detailed description of some embodiments and the presented examples are not intended to limit the scope of the disclosure, but are merely representative of various embodiments. Moreover, the order of steps or acts of the methods disclosed herein may be altered by those skilled in the art without departing from the scope of the disclosure. In other words, unless a specific order of steps or acts is required for proper operation of the embodiment, the order or use of specific steps or acts may be modified.
[0275] Sequence information SEQUENCE LISTING <110> F. Hoffmann-La Roche AG <120> Peptidic linker with reduced post-translational modification <150> EP 18176698.1 <151> 2018-06-08 <160> twenty three <170> PatentIn version 3.5 <210> 1 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> GnSGmX1 <220> <221> CHAIN <222> (1)..(1) <223> X=G or GG or GGG or GGGG <220> <221> CHAIN <222> (3)..(3) <223> X=GGG or GGGG or GGGGG <220> <221> SITE <222> (4)..(4) <220> <221> SITE <222> (4)..(4) <223> X=any amino acid residue except for serine, threonine and proline <400> 1 Xaa Ser Xaa Xaa 1 <210> 2 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> GnSGmX1X2X3 <220> <221> CHAIN <222> (1)..(1) <223> X=G or GG or GGG or GGGG <220> <221> CHAIN <222> (3)..(3) <223> X=GGG or GGGG or GGGGG <220> <221> SITE <222> (4)..(4) <223> X=any amino acid residue except for serine, threonine and proline <220> <221> CHAIN <222> (5)..(6) <223> X=any amino acid residue <400> 2 No Ser No No No No 1 5 <210> 3 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> GpSGnSGmX1X2X3 <220> <221> CHAIN <222> (1)..(1) <223> X = YES or YES <220> <221> CHAIN <222> (3)…(3) <223> X = YES or YES <220> <221> CHAIN <222> (5)…(5) <223> X=GGG or GGGG or GGGGG <220> <221> SITE <222> (6)…(6) <223> X=any amino acid residue except for serine, threonine and proline <220> <221> CHAIN <222> (7)..(8) <223> X=any amino acid residue <400> 3 No Ser No No No No 1 5 <210> 4 <211> 2 <212> PRT <213> Artificial Sequence <220> <223> GyX1 <220> <221> CHAIN <222> (1)..(1) <223> X=Gn with n=3 to 25 <220> <221> SITE <222> (2)..(2) <223> X=any amino acid residue except for serine, threonine and proline <400> 4 Xaa Xaa 1 <210> 5 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> GyX1X2X3 <220> <221> CHAIN <222> (1)..(1) <223> X=Gn with n= 3 to 25 <220> <221> SITE <222> (2)..(2) <223> X=any amino acid residue except for serine, threonine and proline <220> <221> CHAIN <222> (3)..(4) <223> X=any amino acid residue <400> 5 Xaa Xaa Xaa Xaa 1 <210> 6 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> GnSGm(S,T,P)X2X3 <220> <221> CHAIN <222> (1)..(1) <223> X=G or GG or GGG or GGGG <220> <221> CHAIN <222> (3)..(3) <223> X=GGG or GGGG or GGGGG <220> <221> SITE <222> (4)..(4) <223> X=any amino acid residue except for serine, threonine and proline <220> <221> SITE <222> (4)..(4) <223> X=serine, threonine or proline <220> <221> CHAIN <222> (5)..(6) <223> X=any amino acid residue <400> 6 Xaa Ser Xaa Xaa Xaa Xaa 1 5 <210> 7 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> X9GGGGSGGGGSR <220> <221> SITE <222> (1)..(1) <223> X=N-terminal amino acid residue of first non-immunoglobulin polypeptide <220> <221> MOD_RES <222> (11)..(11) <223> phospho-serine PHOSPHORYLATION <400> 7 Xaa Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Arg 1 5 10 <210> 8 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> X9GGGGSGGGGpSR <220> <221> SITE <222> (1)..(1) <223> X=N-terminal amino acid residue of first non-immunoglobulin polypeptide <220> <221> SITE <222> (11)..(11) <223> Xaa can be any naturally occurring amino acid <400> 8 Xaa Gly Gly Gly Gly Ser Gly Gly Gly Gly Xaa Arg 1 5 10 <210> 9 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> X9GGGGSGGGGSREX3 <220> <221> SITE <222> (1)..(1) <223> X=N-terminal amino acid residue of first non-immunoglobulin polypeptide <220> <221> SITE <222> (14)..(14) <223> X=N-terminal amino acid residue of first non-immunoglobulin polypeptide <400> 9 Xaa Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Arg Glu Xaa 1 5 10 <210> 10 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> SLSLSPGGGGGSGGGGSGGGGSGGGGSIQMT <400> 10 Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly 1 5 10 15 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ile Gln Met Thr 20 25 30 <210> 11 <211> 47 <212> PRT <213> Artificial Sequence <220> <223> LC3-F fragment <400> 11 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 1 5 10 15 Gly Gly Ser Gly Gly Gly Gly Thr Cys Pro Pro Cys Pro Ala Pro Glu 20 25 30 Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 35 40 45 <210> 12 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> LC3-F tryptic digest with OpeRATOR protease <400> 12 Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val 1 5 10 15 Phe Leu Phe Pro Pro Lys Pro 20 <210> 13 <211> 49 <212> PRT <213> Artificial Sequence <220> <223> LC3-F tryptic digest without OpeRATOR protease <220> <221> CHAIN <222> (1)..(2) <223> Xaa can be any naturally occurring amino acid <400> 13 Xaa Xaa Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10 15 Gly Gly Gly Gly Ser Gly Gly Gly Gly Thr Cys Pro Pro Cys Pro Ala 20 25 30 Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 35 40 45 Lys <210> 14 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> HC4-F fragment <400> 14 Leu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Arg Thr 1 5 10 <210> 15 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> X8LGGGGSGGGGS(+Fucose)RT <220> <221> SITE <222> (1)..(1) <223> C-terminal amino acid residue of domain 1 <220> <221> MOD_RES <222> (12)..(12) <223> FUCOSYLATED <400> 15 Xaa Leu Gly Gly Gly Gly Ser Gly Gly Gly Gly Xaa Arg Thr 1 5 10 <210> 16 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> repetitive unit GGGS <400> 16 Gly Gly Gly Ser 1 <210> 17 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> repetitive unit GGGGS <400> 17 Gly Gly Gly Gly Ser 1 5 <210> 18 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> GGGGP linker <400> 18 Gly Gly Gly Gly Pro 1 5 <210> 19 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> GGGGSGGGGSRE-peptide fragment <400> 19 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Arg Glu 1 5 10 <210> 20 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> GGGGSGGGGSRT-peptide fragment <400> 20 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Arg Thr 1 5 10 <210> 21 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> GGGSGGGS <400> 21 Gly Gly Gly Ser Gly Gly Gly Ser 1 5 <210> 22 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> GGGGSGGGGS <400> 22 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10 <210> 23 <211> 34 <212> PRT <213> Artificial Sequence <220> <223> GGGSGGGGSGGGGSGGGGSGGGGCPPC-peptide fragment <400> 23 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Cys Pro 20 25 30 Pro Cys
Claims
1. A linear fusion polypeptide comprising a first polypeptide domain, a peptide linker, and a second polypeptide domain, the C-terminus of the first polypeptide domain is conjugated to the N-terminus of the peptide linker via a peptide bond, and the C-terminus of the peptide linker is conjugated to the N-terminus of the second polypeptide domain via a peptide bond; the peptide linker is a Gly / Ser peptide linker lacking a C-terminal serine amino acid residue; the second polypeptide domain comprises at its N-terminus any amino acid residue except serine, threonine, or proline; A linear fusion polypeptide, wherein said first or said second polypeptide domain is an antibody Fc region polypeptide and each other polypeptide is selected from the group consisting of a VH domain, a VL domain, an scFv, an scFab, a VH-CH1 pair, a VL-CL pair, a VH-CL pair, a VL-CH1 pair, a receptor or an extracellular domain thereof, a receptor binding portion of a ligand, an enzyme, a growth factor, an interleukin, a cytokine, or a chemokine.
2. The linear fusion polypeptide has the amino acid sequence GnSGmX1 (SEQ ID NO: 2) GnSGm is a peptide linker with n=3 or 4 and m=3 or 4; 2. The linear fusion polypeptide of claim 1, wherein X1 is the N-terminal amino acid residue of the second polypeptide.
3. 3. The linear fusion polypeptide of claim 1 or 2, wherein the linear fusion polypeptide has reduced O-glycosylation compared to a fusion polypeptide in which the second polypeptide has a serine or threonine or proline at its N-terminus.
4. At least two polypeptides, at least one of which is a linear fusion polypeptide according to any one of claims 1 to 3. A polymeric molecule comprising:
5. The multimeric molecule of claim 4 , wherein the multimeric molecule is an antibody.
6. A nucleic acid molecule encoding a fusion polypeptide according to any one of claims 1 to 3.
7. A eukaryotic cell comprising the nucleic acid molecule of claim 6.
8. 1. A method for producing a linear fusion polypeptide having reduced levels of O-glycosylation, comprising: - culturing the host cell according to claim 7 under conditions in which the fusion polypeptide is expressed, and - recovering said fusion polypeptide from said eukaryotic cells or from said culture medium, Thereby producing a fusion polypeptide having a reduced level of O-glycosylation. A method comprising:
Citation Information
Patent Citations
Covalent diabody and usage thereof
JP2016166209A
A monovalent bispecific diabody that binds to gpA33 and CD3, and its use
JP2017504578A
Polyvalent molecules containing a DR5 binding domain
JP2018507188A
Method for improving the recombinant production of soluble fusion polypeptides
WO2015091130A1
US9.409,960
